[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Endogastric Solutions Inc\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":136},{"warningLetters":4,"total":135},[5,31,49,69,92,117],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":11,"recipient_name":27,"body_fetched_at":28,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":30,"medical_device_id":19,"response_letter_date":19},1431,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-06-11T13:20:00Z\">06\u002F11\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-05-31T04:00:00Z\">05\u002F31\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-solutions-llc-670486-05312024\">Cosmetic Solutions, LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations II","CGMP\u002FFinished Pharmaceuticals\u002FAdulterated","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. John Puckett\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President and COO\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cosmetic Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>6101 Park of Commerce Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Boca Raton\u003C\u002Fspan>, \u003Cspan>FL\u003C\u002Fspan> \u003Cspan>33487-8208\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:johnp@csinnovationlabs.com\"> johnp@csinnovationlabs.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>DATE: 5\u002F31\u002F2024\u003C\u002Fp>\n\n\u003Cp>Case #: 670486\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nDear Mr. Puckett:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Solutions, LLC, FEI 3002692859, at 6101 Park of Commerce Blvd., Boca Raton, from September 12 to 21, 2023.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>In addition, the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\u003C\u002Fp>\n\n\u003Cp>We reviewed your October 11, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>CGMP Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight to ensure procedures for manufacturing your over-the-counter (OTC) drug products were established and followed. For example:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You failed to follow your stability testing procedure. You manufactured multiple batches of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> but have not placed samples of either product into your stability program as required by your procedure (21 CFR 211.166(a) and (b)).\u003C\u002Fli>\n\t\u003Cli>You failed to establish the reliability of your component suppliers’ test analyses at appropriate intervals. You also failed to follow your written procedure for incoming sampling, inspection, and release of raw materials. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products (21 CFR 211.84(d)(2)).\u003C\u002Fli>\n\t\u003Cli>You failed to follow your written change control procedure. During the manufacture of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, you noted the batch became crystallized when cooling to the target temperature range after the addition of phase B ingredients. You then expanded the target temperature range of this batch and subsequent batches outside of the predetermined manufacturing process range. In addition, you added a step to heat a later batch after the addition of phase C ingredients. These changes were executed without following the steps required in your change control procedure (21 CFR 211.100(a)).\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;will be placed on stability. You also explain your supplier qualification procedure has been revised to require sampling and testing of raw materials for comparison with your suppliers’ certificate of analysis (COA). Further, you state you have revised your change control procedure, and you consider this issue closed.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You fail to provide a comprehensive assessment of your stability program that extends to all drug products you manufacture. Further, your response does not include a retrospective assessment of the impact your stability deficiencies have on marketed drug batches within their expiry period.\u003C\u002Fli>\n\t\u003Cli>You fail to assess how the lack of supplier qualification impacts the quality of your marketed drug batches.\u003C\u002Fli>\n\t\u003Cli>You fail to evaluate the quality impact of changes you made outside your change control system to the \u003Cstrong>(b)(4)\u003C\u002Fstrong> manufacturing process. Furthermore, you fail to assess the scope of this issue to determine if manufacturing changes to other drug products were made outside your change control system.\u003C\u002Fli>\n\t\u003Cli>You lack an adequate investigation, including a detailed corrective action and preventive action (CAPA) plan to remediate your firm’s failure to follow approved procedures.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>An adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality.\u003C\u002Fp>\n\n\u003Cp>Your firm’s quality systems are inadequate. See FDA’s guidance document \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fqualitysystems-approach-pharmaceutical-current-good-manufacturing-practice-regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211.\u003C\u002Fp>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A determination of whether procedures used by your firm are robust and appropriate\u003Cbr>\n&nbsp; &nbsp; o Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\u003Cbr>\n&nbsp; &nbsp; o A complete and final review of each batch and its related information before the QU disposition decision\u003Cbr>\n&nbsp; &nbsp; o Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>&nbsp;A comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Stability indicating methods\u003Cbr>\n&nbsp; &nbsp; o Stability studies for each drug product in its marketed container-closure system before distribution is permitted\u003Cbr>\n&nbsp; &nbsp; o An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\u003Cbr>\n&nbsp; &nbsp; o Detailed definition of the specific attributes to be tested at each station (timepoint)\u003Cbr>\n&nbsp; &nbsp; o Improved procedures that describe the listed elements above and any other elements of your remediated stability program\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\u003C\u002Fli>\n\t\u003Cli>A comprehensive assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>A. Lack of Water System Qualification and Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>You failed to qualify your purified water system. You use water from this system as a component in manufacturing drug products, but failed to ensure it consistently produces \u003Cstrong>(b)(4)\u003C\u002Fstrong> water that meets appropriate microbial limits. For example, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water failed microbial testing on several occasions throughout August 2023. Multiple drug batches were manufactured with \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>water during this period. Your investigation failed to identify and quantify the microbial contamination. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of water for use in drug manufacturing operations.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You also failed to adequately validate your alternative rapid microbiological test methods. For example, you use the \u003Cstrong>(b)(4)\u003C\u002Fstrong> system for rapid microbiological testing of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water. You stated this system was validated by the manufacturer, but you failed to verify it upon installation at your facility. Furthermore, you did not demonstrate the system adequately quantifies and identifies objectionable microbes, and you failed to demonstrate it was equivalent to, or better than United States Pharmacopeia (USP) compendial methods, and suitable for its intended use.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cem>B. Lack of Cleaning Validation\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your cleaning validation is inadequate because you did not include all products you manufacture, and all pieces of product-contact equipment currently used for manufacturing your drug products. For example, your cleaning validation protocol did not include various kettles, fillers, and mixers you currently use to manufacture drug products. You also manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products, such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In your response, you state batches manufactured while the water system failed microbial testing were released only after finished product results from an outside laboratory passed.\u003C\u002Fp>\n\n\u003Cp>Additionally, you explain batches manufactured with water from a port that demonstrates microbial contamination will be held until “results” from an outside laboratory are within specification. You also commit to decommissioning a failing port until the investigation and corrective actions are complete. Furthermore, you provide approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> of microbial testing results of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water to show validation of your microbial monitoring system, yet this documentation was not available at the time of the inspection.\u003C\u002Fp>\n\n\u003Cp>You also explain future cleaning validations will be modified by using a revised equipment list, and you will include equipment in contact with active pharmaceutical ingredients (APIs). You will also use \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning verification system where applicable. Furthermore, you state you have engaged a consultant to help implement an enhanced cleaning and sanitization program.\u003C\u002Fp>\n\n\u003Cp>Your response is inadequate.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>You fail to address the lack of qualification and validation of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system.\u003C\u002Fli>\n\t\u003Cli>You lack sound scientific data to demonstrate your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water testing methods are adequate for your firm’s operations. Furthermore, your response does not include identification of the microbes present in your failing water samples and lacks a comprehensive investigation of your water system’s impact on the quality of your drug products. Microbiological contamination is not uniformly distributed, and your plan to test batches until samples are within specification does not scientifically prove your products are free of contaminants. It is essential that stringent upstream controls be employed to assure the quality of a batch.\u003C\u002Fli>\n\t\u003Cli>Additionally, you do not provide an assessment of the impact of your deficient cleaning validation on the quality of your drug products in the market within expiry.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>In response to this letter, provide:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A comprehensive remediation plan for the design, control, and maintenance of the water system.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o A \u003Cstrong>(b)(4)\u003C\u002Fstrong> water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\u003C\u002Fli>\n\t\u003Cli>A detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\u003C\u002Fli>\n\t\u003Cli>A procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>The current action\u002Falert limits for total counts and objectionable organisms used for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water system. Ensure that the total count limits for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> water are appropriately stringent in view of the intended use of each of the products produced by your firm.\u003C\u002Fli>\n\t\u003Cli>A procedure governing your program for monitoring that ensures the system consistently produces water that meets \u003Cstrong>(b)(4)\u003C\u002Fstrong> monograph specifications and appropriate microbial limits.\u003C\u002Fli>\n\t\u003Cli>A validation study of your \u003Cstrong>(b)(4)\u003C\u002Fstrong> microbiological testing system, or other testing system to show it consistently quantifies and identifies microbes as described in \u003Cstrong>(b)(4)\u003C\u002Fstrong> Water monograph.\u003C\u002Fli>\n\t\u003Cli>Appropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>&nbsp; &nbsp; o Drugs with higher toxicities\u003Cbr>\n&nbsp; &nbsp; o Drugs with higher drug potencies\u003Cbr>\n&nbsp; &nbsp; o Drugs of lower solubility in their cleaning solvents\u003Cbr>\n&nbsp; &nbsp; o Drugs with characteristics that make them difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Swabbing locations for areas that are most difficult to clean\u003Cbr>\n&nbsp; &nbsp; o Maximum hold times before cleaning\u003C\u002Fp>\n\n\u003Cp>In addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>A summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cu>\u003Cstrong>Unapproved New Drug Violations\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> product labels and labeling, including the product websites, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003Cbr>\n\u003Cbr>\n\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on the products’ labeled intended uses, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> are “drugs” as defined by section 201(g)(1)(B) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&amp;C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Your \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> products are not generally recognized as safe and effective (GRASE) for their above referenced uses. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. Therefore, these products are “new drugs” within the meaning of section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). In general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&amp;C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, is in effect for \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Thus, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Your written notification should refer to case #\u003Cstrong> 670486\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Please electronically submit your reply, on company letterhead, to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, you may contact Mr. Rivero via phone at (504) 759-7718 or email at mark.rivero@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Monica R. Maxwell\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations,\u003Cbr>\nDivision II\u003C\u002Fp>\n\n\u003Cp>____________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We note your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product is an external analgesic, and your \u003Cstrong>(b)(4)&nbsp;\u003C\u002Fstrong>product is a combination external analgesic and skin protectant drug product, both of which are subject to section 505G of the FD&amp;C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. However, there is no basis under the FD&amp;C Act under which these products would be legally marketed without an approved application. Specifically, with respect to external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in Over-the-Counter (OTC) Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”) and for combination external analgesic and skin protectant drug products, they must conform to the conditions of use set forth in both M017 and OTC Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”). However,&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong> do not conform to the conditions specified in the relevant orders. Neither product is formulated in a manner that is consistent with the applicable final administrative orders and \u003Cstrong>(b)(4)\u003C\u002Fstrong> includes intended uses outside both monographs. Specifically, \u003Cstrong>(b)(4)\u003C\u002Fstrong> is formulated to contain eucalyptus oil, which falls under section 505G(a)(5) of the FD&amp;C Act because FDA has determined that no counterirritant external analgesic products containing eucalyptus oil as an active ingredient are GRASE under a final determination issued under 21 CFR part 330. In addition, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> labeling purports to promote cell repair, which is an intended use not permitted under any OTC Monograph or relevant rulemaking. Although you do not distinguish between active and inactive ingredients for your \u003Cstrong>(b)(4)\u003C\u002Fstrong> product, no combination of the labeled ingredients is permitted by M017 and M016 for a combination external analgesic and skin protectant drug product.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. John Puckett\n\nRecipient Title\n\nPresident and COO\n\nCosmetic Solutions, LLC\n\n6101 Park of Commerce Blvd.\n\nBoca Raton, FL 33487-8208\n\nUnited States\n\njohnp@csinnovationlabs.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations II\n\nUnited States\n\nDATE: 5\u002F31\u002F2024\n\nCase #: 670486\n\nWARNING LETTER\n\nDear Mr. Puckett:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Cosmetic Solutions, LLC, FEI 3002692859, at 6101 Park of Commerce Blvd., Boca Raton, from September 12 to 21, 2023.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nIn addition, the (b)(4), and (b)(4) drug products are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of section 505(a) of the FD&C Act, 21 U.S.C. 355(a). Introduction or delivery for introduction of such products into interstate commerce is prohibited under section 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). These violations are described in more detail below.\n\nWe reviewed your October 11, 2023 response to our Form FDA 483 in detail and acknowledge receipt of your subsequent correspondence.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\nCGMP Violations\n\n1. Your firm failed to establish adequate written responsibilities and procedures applicable to the quality control unit and to follow such written procedures (21 CFR 211.22(d)).\n\nYour quality unit (QU) did not provide adequate oversight to ensure procedures for manufacturing your over-the-counter (OTC) drug products were established and followed. For example:\n\nYou failed to follow your stability testing procedure. You manufactured multiple batches of (b)(4), and (b)(4) but have not placed samples of either product into your stability program as required by your procedure (21 CFR 211.166(a) and (b)).\n\nYou failed to establish the reliability of your component suppliers’ test analyses at appropriate intervals. You also failed to follow your written procedure for incoming sampling, inspection, and release of raw materials. Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications prior to use in the manufacture of your drug products (21 CFR 211.84(d)(2)).\n\nYou failed to follow your written change control procedure. During the manufacture of (b)(4), you noted the batch became crystallized when cooling to the target temperature range after the addition of phase B ingredients. You then expanded the target temperature range of this batch and subsequent batches outside of the predetermined manufacturing process range. In addition, you added a step to heat a later batch after the addition of phase C ingredients. These changes were executed without following the steps required in your change control procedure (21 CFR 211.100(a)).\n\nIn your response, you state (b)(4), and (b)(4) will be placed on stability. You also explain your supplier qualification procedure has been revised to require sampling and testing of raw materials for comparison with your suppliers’ certificate of analysis (COA). Further, you state you have revised your change control procedure, and you consider this issue closed.\n\nYour response is inadequate.\n\nYou fail to provide a comprehensive assessment of your stability program that extends to all drug products you manufacture. Further, your response does not include a retrospective assessment of the impact your stability deficiencies have on marketed drug batches within their expiry period.\n\nYou fail to assess how the lack of supplier qualification impacts the quality of your marketed drug batches.\n\nYou fail to evaluate the quality impact of changes you made outside your change control system to the (b)(4) manufacturing process. Furthermore, you fail to assess the scope of this issue to determine if manufacturing changes to other drug products were made outside your change control system.\n\nYou lack an adequate investigation, including a detailed corrective action and preventive action (CAPA) plan to remediate your firm’s failure to follow approved procedures.\n\nAn adequate QU overseeing all elements of CGMP is necessary to consistently ensure drug product quality.\n\nYour firm’s quality systems are inadequate. See FDA’s guidance document Quality Systems Approach to Pharmaceutical CGMP Regulations at: https:\u002F\u002Fwww.fda.gov\u002Fregulatory-information\u002Fsearch-fda-guidance-documents\u002Fqualitysystems-approach-pharmaceutical-current-good-manufacturing-practice-regulations for help in implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211.\n\nIn response to this letter, provide:\n\nA comprehensive assessment and remediation plan to ensure your QU is given the authority and resources to effectively function. The assessment should also include, but not be limited to:\n\no A determination of whether procedures used by your firm are robust and appropriate\n\no Provisions for QU oversight throughout your operations to evaluate adherence to appropriate practices\n\no A complete and final review of each batch and its related information before the QU disposition decision\n\no Oversight and approval of investigations and discharging of all other QU duties to ensure identity, strength, quality, and purity of all products\n\nA comprehensive independent assessment and CAPA plan to ensure the adequacy of your stability program. Your remediated program should include, but not be limited to:\n\no Stability indicating methods\n\no Stability studies for each drug product in its marketed container-closure system before distribution is permitted\n\no An ongoing program in which representative batches of each product are added each year to the program to determine if the shelf-life claim remains valid\n\no Detailed definition of the specific attributes to be tested at each station (timepoint)\n\no Improved procedures that describe the listed elements above and any other elements of your remediated stability program\n\nA comprehensive independent review of your material system to determine whether all suppliers of components, containers, and closures are each qualified and the materials are assigned appropriate expiration or retest dates. The review should also determine whether incoming material controls are adequate to prevent use of unsuitable components, containers, and closures.\n\nA comprehensive assessment of your change management system. This assessment should include, but not be limited to, your procedure(s) to ensure changes are justified, reviewed, and approved by your QU. Your change management program should also include provisions for determining change effectiveness.\n\n2. Your firm failed to establish adequate written procedures for production and process control designed to assure that drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess, and to follow all of your written production and process control procedures (21 CFR 211.100 (a) and 211.100 (b)).\n\nA. Lack of Water System Qualification and Validation\n\nYou failed to qualify your purified water system. You use water from this system as a component in manufacturing drug products, but failed to ensure it consistently produces (b)(4) water that meets appropriate microbial limits. For example, your (b)(4) water failed microbial testing on several occasions throughout August 2023. Multiple drug batches were manufactured with (b)(4) water during this period. Your investigation failed to identify and quantify the microbial contamination. Routine monitoring of microbial counts and identity of contamination in the system is integral to maintaining a state of control and suitability of water for use in drug manufacturing operations.\n\nYou also failed to adequately validate your alternative rapid microbiological test methods. For example, you use the (b)(4) system for rapid microbiological testing of your (b)(4) water. You stated this system was validated by the manufacturer, but you failed to verify it upon installation at your facility. Furthermore, you did not demonstrate the system adequately quantifies and identifies objectionable microbes, and you failed to demonstrate it was equivalent to, or better than United States Pharmacopeia (USP) compendial methods, and suitable for its intended use.\n\nB. Lack of Cleaning Validation\n\nYour cleaning validation is inadequate because you did not include all products you manufacture, and all pieces of product-contact equipment currently used for manufacturing your drug products. For example, your cleaning validation protocol did not include various kettles, fillers, and mixers you currently use to manufacture drug products. You also manufacture drug products using the same equipment that you use to manufacture nonpharmaceutical products, such as cosmetics. Chemical and microbiological residues on equipment from previous manufacturing activities can adversely impact the purity, quality, and safety of drug products also manufactured on that equipment.\n\nIn your response, you state batches manufactured while the water system failed microbial testing were released only after finished product results from an outside laboratory passed.\n\nAdditionally, you explain batches manufactured with water from a port that demonstrates microbial contamination will be held until “results” from an outside laboratory are within specification. You also commit to decommissioning a failing port until the investigation and corrective actions are complete. Furthermore, you provide approximately (b)(4) of microbial testing results of your (b)(4) water to show validation of your microbial monitoring system, yet this documentation was not available at the time of the inspection.\n\nYou also explain future cleaning validations will be modified by using a revised equipment list, and you will include equipment in contact with active pharmaceutical ingredients (APIs). You will also use (b)(4) cleaning verification system where applicable. Furthermore, you state you have engaged a consultant to help implement an enhanced cleaning and sanitization program.\n\nYour response is inadequate.\n\nYou fail to address the lack of qualification and validation of your (b)(4) water system.\n\nYou lack sound scientific data to demonstrate your (b)(4) water testing methods are adequate for your firm’s operations. Furthermore, your response does not include identification of the microbes present in your failing water samples and lacks a comprehensive investigation of your water system’s impact on the quality of your drug products. Microbiological contamination is not uniformly distributed, and your plan to test batches until samples are within specification does not scientifically prove your products are free of contaminants. It is essential that stringent upstream controls be employed to assure the quality of a batch.\n\nAdditionally, you do not provide an assessment of the impact of your deficient cleaning validation on the quality of your drug products in the market within expiry.\n\nIn response to this letter, provide:\n\nA comprehensive remediation plan for the design, control, and maintenance of the water system.\n\no A (b)(4) water system validation report. Also include the summary of any improvements made to system design and to the program for ongoing control and maintenance.\n\nYour total microbial count limits to monitor whether this system is producing water suitable for the intended uses for each of your products.\n\nA detailed risk assessment addressing the potential effects of the observed water system failures on the quality of all drug product lots currently in U.S. distribution. Specify actions that you will take in response to the risk assessment, such as customer notifications and product recalls.\n\nA procedure for your water system monitoring that specifies routine microbial testing of water to ensure its acceptability for use in each batch of drug products produced by your firm.\n\nThe current action\u002Falert limits for total counts and objectionable organisms used for your (b)(4) Water system. Ensure that the total count limits for your (b)(4) water are appropriately stringent in view of the intended use of each of the products produced by your firm.\n\nA procedure governing your program for monitoring that ensures the system consistently produces water that meets (b)(4) monograph specifications and appropriate microbial limits.\n\nA validation study of your (b)(4) microbiological testing system, or other testing system to show it consistently quantifies and identifies microbes as described in (b)(4) Water monograph.\n\nAppropriate improvements to your cleaning validation program, with special emphasis on incorporating conditions identified as worst case in your drug manufacturing operation. This should include but not be limited to identification and evaluation of all worst-case:\n\no Drugs with higher toxicities\n\no Drugs with higher drug potencies\n\no Drugs of lower solubility in their cleaning solvents\n\no Drugs with characteristics that make them difficult to clean\n\no Swabbing locations for areas that are most difficult to clean\n\no Maximum hold times before cleaning\n\nIn addition, describe the steps that must be taken in your change management system before introduction of new manufacturing equipment or a new product.\n\nA summary of updated standard operating procedures (SOPs) that ensure an appropriate program is in place for verification and validation of cleaning procedures for products, processes, and equipment.\n\nUnapproved New Drug Violations\n\nExamples of claims observed on the (b)(4), and (b)(4) product labels and labeling, including the product websites, that provide evidence of the intended uses (as defined in 21 CFR 201.128) of the products include, but may not be limited to, the following:\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\n(b)(4):\n\n(b)(4)\n\nBased on the products’ labeled intended uses, (b)(4), and (b)(4) are “drugs” as defined by section 201(g)(1)(B) of the FD&C Act, 21 U.S.C. 321(g)(1)(B), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease, and\u002For under section 201(g)(1)(C) of the FD&C Act, 21 U.S.C. 321(g)(1)(C), because they are intended to affect the structure or any function of the body.\n\nYour (b)(4), and (b)(4)1 products are not generally recognized as safe and effective (GRASE) for their above referenced uses. We are not aware of any adequate and well-controlled clinical trials in the published literature that support a determination that these products are generally recognized as safe and effective (GRASE) for use under the conditions prescribed, recommended, or suggested in their labeling. Therefore, these products are “new drugs” within the meaning of section 201(p) of the FD&C Act, 21 U.S.C. 321(p). In general, new drugs may not be introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in section 505(a) of the FD&C Act, 21 U.S.C. 355(a). No FDA-approved application pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, is in effect for (b)(4), and (b)(4).\n\nThus, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nCGMP Consultant Recommended\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to assist your firm in meeting CGMP requirements.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days2. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nYour written notification should refer to case # 670486.\n\nPlease electronically submit your reply, on company letterhead, to Mark W. Rivero, Compliance Officer, at ORAPHARM2_RESPONSES@fda.hhs.gov.\n\nIf you have questions regarding the contents of this letter, you may contact Mr. Rivero via phone at (504) 759-7718 or email at mark.rivero@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nMonica R. Maxwell\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations,\n\nDivision II\n\n____________________\n\n1 We note your (b)(4) product is an external analgesic, and your (b)(4) product is a combination external analgesic and skin protectant drug product, both of which are subject to section 505G of the FD&C Act, 21 U.S.C. 355h, which governs nonprescription drugs marketed without an approved application. However, there is no basis under the FD&C Act under which these products would be legally marketed without an approved application. Specifically, with respect to external analgesic drug products, such products are deemed to be generally recognized as safe and effective (GRASE) and not new drugs if, among other things, they conform to the conditions of use set forth in Over-the-Counter (OTC) Monograph M017: External Analgesic Drug Products for Over-the-Counter Human Use (henceforth “M017”) and for combination external analgesic and skin protectant drug products, they must conform to the conditions of use set forth in both M017 and OTC Monograph M016: Skin Protectant Drug Products for Over-the-Counter Human Use (henceforth “M016”). However, (b)(4) and (b)(4) do not conform to the conditions specified in the relevant orders. Neither product is formulated in a manner that is consistent with the applicable final administrative orders and (b)(4) includes intended uses outside both monographs. Specifically, (b)(4) is formulated to contain eucalyptus oil, which falls under section 505G(a)(5) of the FD&C Act because FDA has determined that no counterirritant external analgesic products containing eucalyptus oil as an active ingredient are GRASE under a final determination issued under 21 CFR part 330. In addition, your (b)(4) labeling purports to promote cell repair, which is an intended use not permitted under any OTC Monograph or relevant rulemaking. Although you do not distinguish between active and inactive ingredients for your (b)(4) product, no combination of the labeled ingredients is permitted by M017 and M016 for a combination external analgesic and skin protectant drug product.\n\n2 Under program enhancements for the Generic Drug User Fee Amendments (GDUFA) reauthorization for fiscal years (FYs) 2023-2027, also known as the GDUFA III Commitment Letter, your facility may be eligible for a Post-Warning Letter Meeting to obtain preliminary feedback from FDA on the adequacy and completeness of your corrective action plans.","Cosmetic Solutions, LLC","cosmetic-solutions-llc-670486-05312024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcosmetic-solutions-llc-670486-05312024","2026-10-26T08:08:18.507651+00:00","Warning Letter","Issued","2024-06-11","670486","Drugs","Mr. John Puckett","2026-08-20T00:02:51.223+00:00","VIA Electronic Mail","2024-05-31",{"id":32,"raw":33,"subject":12,"body_html":38,"body_text":39,"firm_name":40,"letter_id":41,"created_at":18,"fei_number":19,"letter_url":42,"updated_at":43,"action_type":22,"case_status":23,"posted_date":44,"marcs_cms_no":45,"product_type":26,"closeout_date":19,"issuing_office":37,"recipient_name":46,"body_fetched_at":47,"delivery_method":29,"recipient_title":19,"reference_number":19,"action_taken_date":48,"medical_device_id":19,"response_letter_date":19},1227,[34,35,36,37,12,13,13,13],"\u003Ctime datetime=\"2024-10-01T13:20:00Z\">10\u002F01\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-09-06T04:00:00Z\">09\u002F06\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024\">Clean Solutions LLC\u003C\u002Fa>","Division of Pharmaceutical Quality Operations I","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Asim Ozcan\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Clean Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>791 Paulison Ave., Suite 5\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Clifton\u003C\u002Fspan>, \u003Cspan>NJ\u003C\u002Fspan> \u003Cspan>07011-3608\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:asim@cleansolutionsnj.com\"> asim@cleansolutionsnj.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter\u003C\u002Fstrong>\u003Cbr>\nCMS #686995\u003C\u002Fp>\n\n\u003Cp>9\u002F6\u002F2024\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Ozcan:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\u003C\u002Fp>\n\n\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\u003C\u002Fp>\n\n\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\n\n\u003Cp>We reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\u003C\u002Fp>\n\n\u003Cp>During our inspection, our investigators observed specific violations including, but not limited to, the following.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\u003C\u002Fp>\n\n\u003Cp>Without adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\u003C\u002Fp>\n\n\u003Cp>Testing is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>You failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\u003C\u002Fp>\n\n\u003Cp>Process validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\u003C\u002Fp>\n\n\u003Cp>Without adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, \u003Cem>Process Validation: General Principles and Practices\u003C\u002Fem> for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\u003C\u002Fp>\n\n\u003Cp>• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\u003Cbr>\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\u003Cbr>\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\u003Cbr>\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\u003Cbr>\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\u003C\u002Fp>\n\n\u003Cp>An adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>In response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\u003C\u002Fp>\n\n\u003Cp>Based upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\n\n\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003Cbr>\n\u003Cbr>\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\u003C\u002Fp>\n\n\u003Cp>Failure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Send your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\u003C\u002Fp>\n\n\u003Cp>If you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOPQO Division I\u003Cbr>\nU.S. Food and Drug Administration\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Asim Ozcan\n\nRecipient Title\n\nPresident\n\nClean Solutions LLC\n\n791 Paulison Ave., Suite 5\n\nClifton, NJ 07011-3608\n\nUnited States\n\nasim@cleansolutionsnj.com\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter\n\nCMS #686995\n\n9\u002F6\u002F2024\n\nDear Mr. Ozcan:\n\nThe U.S. Food and Drug Administration (FDA) inspected your drug manufacturing facility, Clean Solutions LLC, FEI 3012305678, at 791 Paulison Ave., Suite 5, Clifton, NJ, from May 6 to 10, 2024.\n\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations (CFR), parts 210 and 211 (21 CFR parts 210 and 211).\n\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 351(a)(2)(B).\n\nWe reviewed your May 29, 2024 response to our Form FDA 483 in detail. Your response is inadequate because you failed to provide supportive documentation for evaluation or adequate evidence of corrective actions taken to bring your operations into compliance with CGMP.\n\nDuring our inspection, our investigators observed specific violations including, but not limited to, the following.\n\n1. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\n\nYour firm manufactures over-the-counter (OTC) topical drug products, such as antibacterial hand soaps containing benzalkonium chloride. You failed to perform adequate identity testing of each component lot used in the manufacture of your drug products. You also relied on your suppliers’ certificate of analysis (COA) without establishing the reliability of your component suppliers’ test analyses at appropriate intervals.\n\nWithout adequate testing, you do not have scientific evidence that the components conform to appropriate specifications before use in the manufacture of your drug products.\n\n2. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release, and conduct for each batch of drug product, appropriate laboratory testing, as necessary, required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\n\nYour firm failed to perform appropriate testing on your hand sanitizer and antibacterial hand soap drug products prior to release for distribution. Specifically, during the inspection, you stated that no chemical or microbiological analyses are performed on your finished drug products.\n\nTesting is essential to ensure that the drug products you manufacture conform to all pre-determined quality attributes appropriate for their intended use. Because you lacked adequate testing of each batch of your drug products, you do not know whether they conform to all appropriate finished product specifications and are suitable for release to consumers.\n\n3. Your firm failed to establish written procedures for production and process control designed to assure that the drug products you manufacture have the identity, strength, quality, and purity they purport or are represented to possess (21 CFR 211.100(a)).\n\nYou failed to validate the processes used to manufacture your drug products. You also failed to qualify the equipment used to manufacture your drug products.\n\nProcess validation evaluates the soundness of design and state of control of a process throughout its lifecycle. Each significant stage of a manufacturing process must be designed appropriately and assure the quality of raw material inputs, in-process materials, and finished drugs. Process qualification studies determine whether an initial state of control has been established. Successful process qualification studies are necessary before commercial distribution. Thereafter, ongoing vigilant oversight of process performance and product quality is necessary to ensure that you maintain a stable manufacturing operation throughout the product lifecycle.\n\nWithout adequate process validation, incorporating all manufacturing inputs and parameters that can affect product quality, your firm lacks basic assurance that you can reproducibly deliver products that meet specifications. See FDA's guidance for industry, Process Validation: General Principles and Practices for general principles and approaches that the FDA considers appropriate elements of process validation at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71021\u002Fdownload.\n\n4. Your firm’s quality control unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP, and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\n\nYour quality unit (QU) did not provide adequate oversight for the manufacture of your drug products. For example, your QU failed to ensure the following:\n\n• Establishment of adequate procedures describing complaint handling, change control, and employee training procedures (21 CFR 211.22(d)).\n\n• Establishment of an adequate ongoing stability program (21 CFR 211.166(a)).\n\n• Performance of periodic (i.e., at least annual) product reviews (21 CFR 211.180(e)).\n\n• Adequate equipment cleaning and cleaning procedures, as well as appropriate cleaning validation (21 CFR 211.67(a) and 67(b)).\n\n• Appropriate batch production and control records that include documentation of the accomplishment of each significant step in manufacturing of your drug products (21 CFR 211.188(b)).\n\nAn adequate QU overseeing all manufacturing operations is necessary to consistently ensure drug quality. See FDA’s guidance document Quality Systems approach to Pharmaceutical CGMP Regulations for help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR parts 210 and 211 at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\n\nCGMP Consultant Recommended\n\nIn response to this letter, clarify whether you intend to continue manufacturing drugs at this or any other facility.\n\nBased upon the nature of the violations we identified at your firm, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements if you continue manufacturing drugs. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\n\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\n\nConclusion\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address this matter may result in regulatory or legal action without further notice including, without limitation, seizure and injunction. Unresolved violations may also prevent other Federal agencies from awarding contracts.\n\nFailure to address violations may also cause FDA to withhold issuance of Export Certificates. FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may re-inspect to verify that you have completed corrective actions to address any violations.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nSend your electronic response to orapharm1_responses@fda.hhs.gov. Your written notification should refer to Warning Letter CMS # 686995 and include FEI: 3012305678.\n\nIf you have any questions, contact Compliance Officer Barbara Wilimczyk-Macri at barbara.wilimczyk@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOPQO Division I\n\nU.S. Food and Drug Administration","Clean Solutions LLC","clean-solutions-llc-686995-09062024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fclean-solutions-llc-686995-09062024","2026-10-26T08:08:15.745138+00:00","2024-10-01","686995","Mr. Asim Ozcan","2026-08-19T22:31:53.814+00:00","2024-09-06",{"id":50,"raw":51,"subject":56,"body_html":57,"body_text":58,"firm_name":59,"letter_id":60,"created_at":61,"fei_number":19,"letter_url":62,"updated_at":63,"action_type":22,"case_status":23,"posted_date":64,"marcs_cms_no":65,"product_type":66,"closeout_date":19,"issuing_office":55,"recipient_name":19,"body_fetched_at":67,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":68,"medical_device_id":19,"response_letter_date":19},3127,[52,53,54,55,56,13,13,13],"\u003Ctime datetime=\"2021-10-05T13:20:00Z\">10\u002F05\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-09T04:00:00Z\">08\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021\">Pairon Solutions LLC\u003C\u002Fa>","Center for Devices and Radiological Health","Investigational Device Exemptions (IDE)\u002FPremarket Approval Application (PMA) Adulterated Device","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Medical Devices                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Pairon Solutions LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>13970 SW 72nd Ave\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Portland\u003C\u002Fspan>, \u003Cspan>OR\u003C\u002Fspan> \u003Cspan>97223\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:melissa@paironsolutions.com\"> melissa@paironsolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Devices and Radiological Health\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>DATE: August 9, 2021\u003Cbr>\n\u003Cbr>\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White &amp; Black)\u003C\u002Fp>\n\n\u003Cp>This is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White &amp; Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\u003C\u002Fp>\n\n\u003Cp>FDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White &amp; Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Statements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Statements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Statements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White &amp; Black) that they provide “&gt;95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Statements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Based on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White &amp; Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\u003C\u002Fp>\n\n\u003Cp>In addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\u003C\u002Fp>\n\n\u003Cp>Your website contains a number of false or misleading representations, including but not limited to:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Representations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Representations that Pairon 3Ply Face Masks (Blue, White &amp; Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\u003C\u002Fli>\n\t\u003Cli>Unauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon&nbsp;3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food &amp; Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\u003C\u002Fli>\n\t\u003Cli>Displaying a “Certification of Registration” issued by “Wayborn Quality &amp; Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>To date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White &amp; Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\u003C\u002Fp>\n\n\u003Cp>We remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration &amp; Device Listing Database merely denotes that the establishment has provided certain information to FDA.\u003C\u002Fp>\n\n\u003Cp>This letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\u003C\u002Fp>\n\n\u003Cp>Food and Drug Administration\u003Cbr>\nCenter for Devices and Radiological Health\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nDivision of Regulatory Programs 2: Establishment Support\u003Cbr>\nRegulatory Inspections and Audits Team\u003Cbr>\nWhite Oak Building 66\u003Cbr>\n10903 New Hampshire Ave.\u003Cbr>\nSilver Spring, MD 20993\u003C\u002Fp>\n\n\u003Cp>Refer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Donna Engleman, MS, BSN\u003Cbr>\nDirector\u003Cbr>\nDivision of Market Intelligence\u003Cbr>\nOffice of Regulatory Programs\u003Cbr>\nOffice of Product Evaluation and Quality\u003Cbr>\nCenter for Devices and Radiological Health\u003C\u002Fp>\n\n\u003Cp>&nbsp;\u003C\u002Fp>\n\n\u003Cp>Cc:\u003C\u002Fp>\n\n\u003Cp>Yabo Zhang\u003Cbr>\nDongguan Arun Industrial, Co., Ltd.\u003Cbr>\nNO.18Xingfeng St, Changlong, Huangjiang\u003Cbr>\nDongguan, CN 523766\u003C\u002Fp>\n\n\u003Cp>US Agent:\u003Cbr>\nSimcal\u003Cbr>\nUCL-REG SERVICE INC.\u003Cbr>\n3907 Prince Street Suite 6F\u003Cbr>\nFlushing, NY 11354\u003Cbr>\nEmail: gbstandard@163.com\u003C\u002Fp>\n\n\u003Cp>UCL-Reg Service\u003Cbr>\n602 ROCKWOOD ROAD, WILMINGTON\u003Cbr>\nNew Castle, DE, 19802\u003C\u002Fp>\n\n\u003Cp>XIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\u003Cbr>\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\u003Cbr>\nHubei Province, P.R. China\u003Cbr>\nXiantao, CN 433018\u003C\u002Fp>\n\n\u003Cp>Leeyeo Kee\u003Cbr>\nRegrek LLC\u003Cbr>\n19 Holly Cove Ln.\u003Cbr>\nDover, DE 19901\u003Cbr>\nEmail: regrek.cs@hotmail.com\u003C\u002Fp>\n\n\u003Cp>Sungo Technical Services Inc.\u003Cbr>\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\u003Cbr>\nE-mail：sungo.group@yahoo.com\u003Cbr>\nEmail: Shage2008@126.com\u003C\u002Fp>\n\n\u003Cp>WUXI HINGDOU SPORTS CO., LTD\u003Cbr>\nHongdou Industrial Park, Donggang Town\u003Cbr>\nWuxi, Jiangsu, 214000, China\u003C\u002Fp>\n\n\u003Cp>Director: Crane Yu\u003Cbr>\nWayborn Quality &amp; Technology Services\u003Cbr>\n306, Xincheng International Main Building,\u003Cbr>\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\u003Cbr>\nEmail: wayborn@wayb.org\u003C\u002Fp>\n\n\u003Cp>___________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1&nbsp;\u003C\u002Fstrong>\u003C\u002Fem>The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: \u003Ca href=\"https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\">https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy\u003C\u002Fa>)\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nMedical Devices\n\nRecipient:\n\nPairon Solutions LLC\n\n13970 SW 72nd Ave\n\nPortland, OR 97223\n\nUnited States\n\nmelissa@paironsolutions.com\n\nIssuing Office:\n\nCenter for Devices and Radiological Health\n\nUnited States\n\nWARNING LETTER\n\nDATE: August 9, 2021\n\nRe: “Arun KN95 Folding Face Mask,” “Deming Surgical Mask,” and “Pairon 3Ply Face Mask” (Blue, White & Black)\n\nThis is to advise you that the United States Food and Drug Administration (FDA) reviewed your website at the Internet address https:\u002F\u002Fwww.paironsolutionsppe.com\u002F on July 14, 2021. The FDA has observed that your website offers the “Arun KN95 Folding Face Mask,” the “Deming Surgical Mask”, and the “Pairon 3Ply Face Mask” (Blue, White & Black) for sale in the United States. Based on our review, these products are devices because they are intended for use in the diagnosis of disease or other conditions or in the cure, mitigation, treatment, or prevention of disease, or to affect the structure or any function of the body, and thus, are devices under section 201(h) of the Federal Food, Drug, and Cosmetic Act (the “Act”), 21 U.S.C. § 321(h).\n\nFDA’s review of your website revealed the following statements that establish that the Arun KN95 Folding Face Mask, Deming Surgical Mask, and Pairon 3Ply Face Mask (Blue, White & Black) are intended for the mitigation, prevention, treatment, diagnosis, or cure of disease, including but not limited to:\n\nStatements made alongside an image of the Arun KN95 Folding Face Mask that it is “listed on FDA EUA for Non-NIOSH Devices” and representing compliance with “GB2626-2006” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nStatements alongside an image of the Deming Surgical Mask that it provides “99% bacterial efficiency” and “complies ASTM F2100”. The name also incorporates the word “surgical” as well as “medical” written on the box packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nStatements made on the packaging and alongside the images of the Pairon 3Ply Face Mask (Blue, White & Black) that they provide “>95% bacterial efficiency” and “helps filter out … bacteria” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-facemask], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black], [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nStatements on your firm’s customer blog page representing that the BLUE – Pairon 3Ply Face Mask has been supplied to nursing home facilities [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fblogs\u002Fnews]\n\nBased on our review, your website is offering for sale in the United States, the Arun KN95 Folding Face Mask (which your website represents is manufactured by Dongguan Arun Industrial Co. Ltd.), the Deming Surgical Mask (which your website represents is manufactured by Xiantao Deming Healthcare Products Co., Ltd.), and the Pairon 3Ply Face Mask - Blue, White & Black (which your website represents is manufactured by Wuxi Hingdou Sports Co., Ltd) without marketing approval or clearance from the FDA. Accordingly, these products are adulterated under section 501(f)(1)(B) of the Act, 21 U.S.C. § 351(f)(1)(B), because your firm does not have an approved application for premarket approval (PMA) in effect pursuant to section 515(a) of the Act, 21 U.S.C. § 360e(a), or an approved application for an investigational device exemption (IDE) under section 520(g) of the Act, 21 U.S.C. § 360j(g). These products are also misbranded under section 502(o) of the Act, 21 U.S.C. § 352(o), because your firm did not notify the agency of its intent to introduce the devices into commercial distribution, as required by section 510(k) of the Act, 21 U.S.C. § 360(k).\n\nIn addition, these products are misbranded under section 502(a) of the Act, 21 U.S.C. § 352(a), because their labeling is false or misleading. FDA registration of a device establishment or assignment of a registration number does not denote FDA approval of the establishment or the device. Thus, references to a firm’s establishment registration and registration number that create an impression of official FDA approval, clearance, authorization, certification, endorsement or other evaluation of the establishment or the devices are misleading and constitute misbranding. See 21 CFR 807.39.\n\nYour website contains a number of false or misleading representations, including but not limited to:\n\nRepresentations that the Arun KN95 Folding Face Masks are “Certified: … FDA” and unauthorized display of what appears to be FDA’s logo1 on inner packaging of the product [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nRepresentations that the Deming Surgical Masks are “Certified: FDA” and unauthorized display of what appears to be FDA’s logo on packaging [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nRepresentations that Pairon 3Ply Face Masks (Blue, White & Black) are “FDA Registered” [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask] [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3ply-face-mask-black][https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fwhite-pairon-3ply-face-mask]\n\nUnauthorized display of what appears to be FDA’s logo alongside the BLACK – Pairon 3Ply Face Mask [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fcopy-of-pairon-3plyface-mask-black]\n\nDisplaying a “Certificate of FDA Registration” issued by “UCL-REGSERVICE INC” (UCL-REGSERVICE Certificate) alongside Arun KN95 Folding Face Mask product information. The UCL-REGSERVICE Certificate “certifies that Dongguan Arun Industrial Co. Ltd., …has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The UCL-REGSERVICE Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo1 and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fkn95-mask]\n\nDisplaying a “Certification of Registration” issued by “Sungo Technical Services Inc.” (Sungo Technical Certificate) alongside Deming Surgical Mask product information. The Sungo Technical Certificate “certifies that Xiantao Deming Healthcare Products Co., Ltd., … has completed the FDA Establishment Registration and Device Listing with the US Food & Drug Administration…” The Sungo Technical Certificate has the look of an official government document, and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag) [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fsurgical-mask]\n\nDisplaying a “Certification of Registration” issued by “Wayborn Quality & Technology Services” (Wayborn Certificate) alongside the BLUE – Pairon 3Ply Face Mask product information. The Wayborn Certificate “certifies that … Wuxi Hingdou Sports Co., Ltd., …has completed U.S. FOOD And DRUG Administration Medical Device Registration…” The Wayborn Certificate has the look of an official government document and incorporates unauthorized use of the FDA logo and an illustration of an eagle with a U.S. flag (or a similar flag). [https:\u002F\u002Fwww.paironsolutionsppe.com\u002Fproducts\u002Fgeneral-use-face-mask]\n\nTo date, FDA has not cleared, approved, authorized or “Certified” the Arun KN95 Folding Face Mask or the Deming Surgical Mask offered for sale by your firm, and so statements to the contrary are false. In addition, display of the FDA logo on packaging and near images of and information about the Arun KN95 Folding Face Mask, the Deming Surgical Mask, and the Pairon 3Ply Face Mask (Blue, White & Black), combined with statements such as, “Certified: FDA” and “FDA Registered”, are misleading because it creates the impression of official FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the devices and\u002For your establishment.. The UCL-REGSERVICE Certificate bearing the FDA logo, positioned near images of and information about the Arun KN95 Folding Face Mask is misleading because it implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishment based on the representations that Dongguan Arun Industrial, Co., Ltd. is or was registered with FDA and that the firm is or was in possession of a registration number. In addition, the display of Sungo Technical Certificate bearing the FDA logo positioned near images of and information about the Deming Surgical Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Xiantao Deming Healthcare Products Co., Ltd. registration and possession of a registration number. Furthermore, display of the Wayborn Certificate bearing the FDA logo, near information about the BLUE – Pairon 3Ply Face Mask is misleading because such display implies FDA approval, clearance, authorization, certification, endorsement, or other evaluation of the product and\u002For establishments based on the existence of Wuxi Hingdou Sports Co., Ltd registration and possession of a registration number. Although the Arun KN95 Folding Face Mask, Deming Surgical Mask, and BLUE – Pairon 3Ply Face Mask Certificates contain legible language that appears to be intended to function as a disclaimer, including a statement that the Certificates do not denote FDA endorsement or approval, statements that FDA does not issue or recognize certificates of registration, and a statement that quotes 21 CFR 807.39, the small font size and overall placement of such language could be easily overlooked and does not limit or otherwise mitigate the misleading impression created by the use of the Certificates. Such representations are especially concerning from a public health perspective because consumers rely on information provided by sellers to determine whether to purchase a device and your presentation conveys the misimpression that the products have been reviewed and approved by FDA.\n\nWe remind you that FDA’s Center for Devices and Radiological Health (CDRH) does not issue device registration certificates to medical device establishments, including to sellers and manufacturers. When an establishment registers and lists its devices, the resulting entry in FDA’s Establishment Registration & Device Listing Database merely denotes that the establishment has provided certain information to FDA.\n\nThis letter is not meant to be an all-inclusive list of violations that exist in connection with the products or your operations. It is your responsibility to ensure that the products you sell are in compliance with the Act and its implementing regulations. We advise you to review your website, product labels, and other labeling and promotional materials to ensure that you do not make representations that misbrand the product(s) in violation of the Act.\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. Please notify this office in writing within fifteen (15) business days from the date you receive this letter of the specific steps your firm has taken to address the noted violations, as well as an explanation of how your firm plans to prevent these violations, or similar violations, from occurring again. Include documentation of any actions your firm has taken. If your firm’s planned actions will occur over time, please include a timetable for implementation of those activities. Your firm’s response should be comprehensive and address all violations included in this letter. If you believe that the products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour firm’s response should be sent via email to CDRHWarningLetterResponses@fda.hhs.gov or by mail to:\n\nFood and Drug Administration\n\nCenter for Devices and Radiological Health\n\nOffice of Regulatory Programs\n\nDivision of Regulatory Programs 2: Establishment Support\n\nRegulatory Inspections and Audits Team\n\nWhite Oak Building 66\n\n10903 New Hampshire Ave.\n\nSilver Spring, MD 20993\n\nRefer to the Document number CMS Case# 616392 or CTS Number CPT2001233 when replying. We remind you that only written communication is considered as official. If you have any questions about the contents of this letter, please contact: Assistant Director, Paola Barnett at 301-796-5462 or Paola.Barnett@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nDonna Engleman, MS, BSN\n\nDirector\n\nDivision of Market Intelligence\n\nOffice of Regulatory Programs\n\nOffice of Product Evaluation and Quality\n\nCenter for Devices and Radiological Health\n\nCc:\n\nYabo Zhang\n\nDongguan Arun Industrial, Co., Ltd.\n\nNO.18Xingfeng St, Changlong, Huangjiang\n\nDongguan, CN 523766\n\nUS Agent:\n\nSimcal\n\nUCL-REG SERVICE INC.\n\n3907 Prince Street Suite 6F\n\nFlushing, NY 11354\n\nEmail: gbstandard@163.com\n\nUCL-Reg Service\n\n602 ROCKWOOD ROAD, WILMINGTON\n\nNew Castle, DE, 19802\n\nXIANTAO DEMING HEALTHCARE PRODUCTS CO., LTD.\n\nNo.198, Pengchang Ave. Pengchang Town, Xiantao City\n\nHubei Province, P.R. China\n\nXiantao, CN 433018\n\nLeeyeo Kee\n\nRegrek LLC\n\n19 Holly Cove Ln.\n\nDover, DE 19901\n\nEmail: regrek.cs@hotmail.com\n\nSungo Technical Services Inc.\n\n6050 W Eastwood Ave Apt. 201 Chicago Illinois 60630\n\nE-mail：sungo.group@yahoo.com\n\nEmail: Shage2008@126.com\n\nWUXI HINGDOU SPORTS CO., LTD\n\nHongdou Industrial Park, Donggang Town\n\nWuxi, Jiangsu, 214000, China\n\nDirector: Crane Yu\n\nWayborn Quality & Technology Services\n\n306, Xincheng International Main Building,\n\nNo.535 Qingshuiqiao Road, Ningbo High-tech Zone\n\nEmail: wayborn@wayb.org\n\n___________________________\n\n1 The FDA logo is for official use by FDA and not for private use on labeling of FDA-regulated products. See FDA Logo Policy (available at: https:\u002F\u002Fwww.fda.gov\u002Fabout-fda\u002Fwebsite-policies\u002Ffda-logo-policy)","Pairon Solutions LLC","pairon-solutions-llc-616392-08092021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fpairon-solutions-llc-616392-08092021","2026-10-26T08:09:39.952179+00:00","2021-10-05","616392","Medical Devices","2026-08-20T02:35:05.169+00:00","2021-08-09",{"id":70,"raw":71,"subject":76,"body_html":77,"body_text":78,"firm_name":79,"letter_id":80,"created_at":81,"fei_number":19,"letter_url":82,"updated_at":83,"action_type":22,"case_status":23,"posted_date":84,"marcs_cms_no":85,"product_type":86,"closeout_date":19,"issuing_office":75,"recipient_name":87,"body_fetched_at":88,"delivery_method":89,"recipient_title":19,"reference_number":90,"action_taken_date":91,"medical_device_id":19,"response_letter_date":19},22012,[72,73,74,75,76,13,13,13],"\u003Ctime datetime=\"2026-10-27T04:00:00Z\">10\u002F27\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-10-22T04:00:00Z\">10\u002F22\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026\">TSP Solutions Pte. Ltd.\u003C\u002Fa>","Center for Drug Evaluation and Research (CDER)","Request for Records\u002FCGMP\u002FFinished Pharmaceuticals\u002FAdulterated\u002FOTC","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>320-27-07\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n                          \u003Cbr>Over-the-Counter Drugs\n                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Min-tsek Lau\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Managing Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>TSP Solutions Pte. Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>Block 998 Toa Payoh North\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>#05-05\u002F06 Mapletree Industrial\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>318993\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Singapore\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:mintsek@tspsolutions.co\"> mintsek@tspsolutions.co\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 22, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>Reference number: 320-27-07\u003C\u002Fp>\u003Cp>To Mr. Min-tsek Lau:\u003C\u002Fp>\u003Cp>This warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\u003C\u002Fp>\u003Cp>\u003Cstrong>FDA Review\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Violations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\u003C\u002Fp>\u003Cp>Your facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) for your facility.\u003C\u002Fp>\u003Cp>This warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\u003C\u002Fp>\u003Cp>Because your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. 351(a)(2)(B)).\u003C\u002Fp>\u003Cp>\u003Cstrong>Violations of the Federal Food, Drug, and Cosmetic Act\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>The following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\u003C\u002Fp>\u003Cp>\u003Cstrong>1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Your firm manufactures sunscreen drug products.\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\u003C\u002Fp>\u003Cp>Full release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\u003C\u002Fli>\u003Cli>An action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\u003C\u002Fli>\u003Cli>A summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\u003C\u002Fp>\u003Cp>Without adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\u003C\u002Fp>\u003Cp>In response to this letter, provide:\u003C\u002Fp>\u003Cul>\u003Cli>A comprehensive, independent review of your material system, including but not limited to:\u003Cbr>o evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\u003Cbr>o an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\u003Cbr>o a review to ensure assigned expiration or retest dates are appropriate (supported by data)\u003Cbr>o adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\u003Cbr>o vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\u003Cbr>o based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\u003C\u002Fli>\u003Cli>The chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\u003C\u002Fli>\u003Cli>A description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\u003C\u002Fli>\u003Cli>A summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\u003C\u002Fli>\u003Cli>A summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\u003C\u002Fli>\u003C\u002Ful>\u003Cp>\u003Cstrong>3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\u003C\u002Fp>\u003Cul>\u003Cli>Adequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\u003C\u002Fli>\u003Cli>Adequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\u003C\u002Fli>\u003Cli>The establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\u003C\u002Fli>\u003C\u002Ful>\u003Cp>Your firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents \u003Cem>Quality Systems Approach to Pharmaceutical CGMP Regulations\u003C\u002Fem> at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\u003C\u002Fp>\u003Cp>\u003Cstrong>CGMP Consultant Recommended\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Based upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\u003C\u002Fp>\u003Cp>Your use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>As previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\u003C\u002Fp>\u003Cp>FDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\u003C\u002Fp>\u003Cp>FDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\u003C\u002Fp>\u003Cp>Failure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&amp;C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&amp;C Act, 21 U.S.C. 351(a)(2)(B).\u003C\u002Fp>\u003Cp>Send your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\u003C\u002Fp>\u003Cp>If you have information that you believe demonstrates that your products are not in violation of the FD&amp;C Act and FDA regulations, include that information for our consideration.\u003C\u002Fp>\u003Cp>FDA posts warning letters to www.FDA.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Francis Godwin\u003Cbr>Director\u003Cbr>Office of Manufacturing Quality\u003Cbr>Office of Compliance\u003Cbr>Center for Drug Evaluation and Research\u003Cbr>U.S. Food and Drug Administration\u003C\u002Fp>\u003Cp>Cc: Registered U.S. Agent\u003Cbr>Mr. David Lennarz\u003Cbr>Registrar Corp\u003Cbr>drugs@registrarcorp.com\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED\n\nReference #:\n\n320-27-07\n\nProduct:\n\nDrugs\n\nOver-the-Counter Drugs\n\nRecipient:\n\nRecipient Name\n\nMr. Min-tsek Lau\n\nRecipient Title\n\nManaging Director\n\nTSP Solutions Pte. Ltd.\n\nBlock 998 Toa Payoh North\n\n#05-05\u002F06 Mapletree Industrial\n\n318993\n\nSingapore\n\nmintsek@tspsolutions.co\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nOctober 22, 2026\nWARNING LETTER\nReference number: 320-27-07\nTo Mr. Min-tsek Lau:\nThis warning letter advises you of significant violations identified during a U.S. Food and Drug Administration (FDA) review of records submitted from your facility. Promptly address the violations described herein without delay, including ensuring that appropriate resources are allocated to fully address the violations and prevent their recurrence. This is not intended to be an all-inclusive list of the violations that exist at your facility. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations. Failure to adequately address violations may result in regulatory action without further notice.\nFDA Review\nViolations were identified and documented during review of your drug manufacturing facility, TSP Solutions Pte. Ltd., FDA Establishment Identifier (FEI) 3023093622. This review was conducted under FDA’s statutory authority and public health responsibilities to protect the public from unsafe, ineffective, and poor quality drugs.\nYour facility is registered with the United States Food and Drug Administration (FDA) as a manufacturer of over-the-counter (OTC) drug products. FDA has reviewed the records you submitted in response to our September 9, 2025, request and subsequent correspondence, for records and other information pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) for your facility.\nThis warning letter summarizes significant violations of Current Good Manufacturing Practice (CGMP) regulations for finished pharmaceuticals. See Title 21 Code of Federal Regulations, parts 210 and 211 (21 CFR, parts 210 and 211).\nBecause your methods, facilities, or controls for manufacturing, processing, packing, or holding of drugs as described in your response to our 704(a)(4) request do not conform to CGMP, your drug products are adulterated within the meaning of section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. 351(a)(2)(B)).\nViolations of the Federal Food, Drug, and Cosmetic Act\nThe following are violations identified during our review. As a reminder, this is not an all-inclusive list of violations at your facility.\n1. Your firm failed to have, for each batch of drug product, appropriate laboratory determination of satisfactory conformance to final specifications for the drug product, including the identity and strength of each active ingredient, prior to release; and, your firm failed to conduct appropriate laboratory testing, as necessary, for each batch of drug product required to be free of objectionable microorganisms (21 CFR 211.165(a) and 211.165(b)).\nYour firm manufactures sunscreen drug products.\nBased on the records and information you provided, you did not demonstrate that you conduct adequate finished drug product testing on your drug products. Specifically, neither the certificate of analysis (COA) reports nor the batch records that you provided include an appropriate assay test for active ingredient content or impurity testing. In addition, your records do not include appropriate microbiological testing.\nFull release testing, including strength and identity testing of the active ingredient, as well as appropriate microbiological testing, must be performed before drug product release and distribution. Without adequate testing, you do not have adequate scientific evidence to ensure that your drug products conform to appropriate specifications before release.\nIn response to this letter, provide:\nA list of chemical and microbial specifications, including test methods, used to analyze each batch of your drug products before a lot disposition decision.\nAn action plan and timelines for conducting full chemical and microbiological testing of retain samples to determine the quality of all batches of drug product distributed to the United States that are within expiry as of the date of this letter.\nA summary of all results obtained from testing retain samples from each batch. If such testing reveals substandard quality drug products, take rapid corrective actions, such as notifying customers and product recalls.\n2. Your firm failed to conduct at least one test to verify the identity of each component of a drug product. Your firm also failed to validate and establish the reliability of your component supplier’s test analyses at appropriate intervals (21 CFR 211.84(d)(1) and 211.84(d)(2)).\nBased on the records and information you provided, you did not demonstrate that you are adequately testing the identity of incoming components used in the manufacture of your drug products. Your response also indicated that you accept your supplier’s COA without verifying the test results at appropriate intervals. Verification of component quality is performed only by reviewing the COAs and material safety data sheets provided by the suppliers.\nWithout adequate testing and without establishing the reliability of your component suppliers’ test analyses at appropriate intervals, you do not have scientific evidence that your raw materials conform to appropriate specifications before you use them in the manufacture of your drug products. As a manufacturer, you have a responsibility to sample, test, and examine drug components before you use them in production to ensure adequate quality.\nIn response to this letter, provide:\nA comprehensive, independent review of your material system, including but not limited to:\no evaluating all suppliers of materials (components, containers, and closures) to determine if they are reliable and appropriately qualified\no an assessment of all materials to determine whether they are consistently of acceptable quality based on thorough historical review\no a review to ensure assigned expiration or retest dates are appropriate (supported by data)\no adequacy of the supplier qualification program, and its selection, qualification, and disqualification provisions\no vigilant lifecycle monitoring of all suppliers using sound quality risk management practices\no based on this thorough review, summarize a systemic CAPA that remediates the materials system to ensure ongoing lifecycle oversight of vendor performance and prevents use of unsuitable components (ingredients), containers and closures.\nThe chemical and microbiological quality control specifications you use to test and release each incoming lot of component for use in manufacturing.\nA description of how you will test each component lot for conformity with all appropriate specifications for identity, strength, quality, and purity. If you intend to accept any results from your supplier’s COA instead of testing each component lot for strength, quality, and purity, specify how you will robustly establish the reliability of your supplier’s results through initial validation as well as periodic re-validation. In addition, include a commitment to always conduct at least one specific identity test for each incoming component lot.\nA summary of results obtained from testing all components to evaluate the reliability of the COA from each component manufacturer. Include your SOP that describes this COA validation program.\nA summary of your program for qualifying and overseeing contract facilities that test the components and drug products you manufacture.\n3. Your firm’s quality unit failed to exercise its responsibility to ensure drug products manufactured are in compliance with CGMP and meet established specifications for identity, strength, quality, and purity (21 CFR 211.22).\nBased on the records and information you provided, your firm failed to establish an adequate quality unit (QU) with the responsibilities and authority to oversee the manufacturing of drug products. For example, your QU failed to ensure:\nAdequate procedures ensuring appropriate production and process controls for drug product manufacturing and qualification of equipment used to manufacture drug products (21 CFR 211.100(a)).\nAdequate laboratory control procedures to ensure drug products conform to appropriate standards of identity, strength, quality, and purity (21 CFR 211.160(b)).\nThe establishment of an adequate, ongoing stability program (21 CFR 211.166(a)).\nYour firm’s quality systems are inadequate. For help implementing quality systems and risk management approaches to meet the requirements of CGMP regulations 21 CFR, parts 210 and 211, see FDA’s guidance documents Quality Systems Approach to Pharmaceutical CGMP Regulations at https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F71023\u002Fdownload.\nCGMP Consultant Recommended\nBased upon the nature of the violations we identified in your response, you should engage a consultant qualified as set forth in 21 CFR 211.34 to evaluate your operations and to assist your firm in meeting CGMP requirements. The qualified consultant should also perform a comprehensive six-system audit of your entire operation for CGMP compliance and evaluate the completion and efficacy of your corrective actions and preventive actions before you pursue resolution of your firm’s compliance status with FDA.\nYour use of a consultant does not relieve your firm’s obligation to comply with CGMP. Your firm’s executive management remains responsible for resolving all deficiencies and systemic flaws to ensure ongoing CGMP compliance.\nConclusion\nAs previously stated, you are responsible for investigating and determining the root causes of any violations and implementing corrective and preventative measures to ensure future and sustained compliance so that these violations and any others do not occur.\nFDA placed all drugs and drug products offered for import into the United States from your firm on Import Alert 66-40 on August 14, 2026.\nFDA may withhold approval of new applications or supplements listing your firm as a drug manufacturer until any violations are completely addressed and we confirm your compliance with CGMP. We may inspect to verify that you have completed corrective actions to any violations.\nFailure to address any violations may also result in the FDA continuing to refuse admission of articles manufactured at TSP Solutions Pte. Ltd., at Block 998 Toa Payoh North, #05-05\u002F06 Mapletree Industrial, Singapore 318993, Singapore, into the United States under section 801(a)(3) of the FD&C Act, 21 U.S.C. 381(a)(3). Articles under this authority that appear to be adulterated may be detained or refused admission, in that the methods and controls used in their manufacture do not appear to conform to CGMP within the meaning of section 501(a)(2)(B) of the FD&C Act, 21 U.S.C. 351(a)(2)(B).\nSend your written response to CDER-OC-OMQ-Communications@fda.hhs.gov within 15 business days of receipt of this letter. Identify your written response with FEI 3023093622 and ATTN: Bryce Hammer in the subject line of the email.\nIf you have information that you believe demonstrates that your products are not in violation of the FD&C Act and FDA regulations, include that information for our consideration.\nFDA posts warning letters to www.FDA.gov.\nSincerely,\n\u002FS\u002F\nFrancis Godwin\nDirector\nOffice of Manufacturing Quality\nOffice of Compliance\nCenter for Drug Evaluation and Research\nU.S. Food and Drug Administration\nCc: Registered U.S. Agent\nMr. David Lennarz\nRegistrar Corp\ndrugs@registrarcorp.com","TSP Solutions Pte. Ltd.","tsp-solutions-pte-ltd-735071-10222026","2026-11-03T01:02:17.615107+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Ftsp-solutions-pte-ltd-735071-10222026","2026-11-17T01:02:03.701861+00:00","2026-10-27","735071","Drugs Over-the-Counter Drugs","Mr. Min-tsek Lau","2026-11-03T01:03:12.526+00:00","VIA ELECTRONIC MAIL READ\u002FDELIVERY RECEIPT REQUESTED","320-27-07","2026-10-22",{"id":93,"raw":94,"subject":101,"body_html":102,"body_text":103,"firm_name":104,"letter_id":105,"created_at":106,"fei_number":19,"letter_url":107,"updated_at":108,"action_type":22,"case_status":109,"posted_date":110,"marcs_cms_no":111,"product_type":26,"closeout_date":112,"issuing_office":37,"recipient_name":113,"body_fetched_at":114,"delivery_method":115,"recipient_title":19,"reference_number":19,"action_taken_date":116,"medical_device_id":19,"response_letter_date":19},2025,[95,96,97,98,99,13,100,13],"\u003Ctime datetime=\"2023-06-27T13:20:00Z\">06\u002F27\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-06-08T04:00:00Z\">06\u002F08\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-06082023\">Safe Chain Solutions, LLC\u003C\u002Fa>"," Division of Pharmaceutical Quality Operations I","Drug Product\u002FAdulterated\u003Cbr \u002F>\r\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-03102025\">\u003Ctime datetime=\"2025-03-17T04:00:00Z\">03\u002F17\u002F2025\u003C\u002Ftime>\n\u003C\u002Fa>","Drug Product\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Charles D. Boyd\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Founder and Chief Executive Officer\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Safe Chain Solutions, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>822 Chesapeake Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cambridge\u003C\u002Fspan>, \u003Cspan>MD\u003C\u002Fspan> \u003Cspan>21613-9408\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Pharmaceutical Quality Operations I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>Warning Letter #636044\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>June 08, 2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Boyd:\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) inspected your wholesale drug distribution facility, Safe Chain Solutions, LLC (Safe Chain), FEI 3009729473, at 822 Chesapeake Drive, Cambridge, Maryland from April 11 to May 11, 2022.\u003C\u002Fp>\n\n\u003Cp>The Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added Section 582 to the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act). Section 582 of the FD&amp;C Act (21 U.S.C. 360eee-1) states the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors) must follow related to product tracing, verification, and authorized trading partners. This warning letter summarizes significant violations of the requirements found in section 582(c) of the FD&amp;C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\u003C\u002Fp>\n\n\u003Cp>FDA issued a Form FDA 483 to Safe Chain at its Cambridge, MD headquarters on May 10, 2022. FDA reviewed your firm’s response, dated June 1, 2022.\u003C\u002Fp>\n\n\u003Cp>FDA has observed that Safe Chain did not have adequate verification systems in place in violation of section 582(c)(4)(A) &amp; (B) of the FD&amp;C Act. FDA observed that Safe Chain failed to maintain records regarding suspect product investigations in violation of section 582(c)(4)(A)(iii) of the FD&amp;C Act, and failed to respond to a notification of illegitimate product in violation of section 582(c)(4)(B)(iii) of the FD&amp;C Act. In addition, Safe Chain engaged in transactions with unauthorized trading partners in violation of section 582(c)(3) of the FD&amp;C Act. Failure to comply with any of the requirements under section 582 of the FD&amp;C Act is a prohibited act under section 301(t) of the FD&amp;C Act (21 U.S.C. 331(t)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>DSCSA Violations\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>1. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA (FD&amp;C Act Section 582(c)(4)(A) &amp; (B)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Under section 582(c)(4)(A) &amp; (B) of the FD&amp;C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA.\u003C\u002Fp>\n\n\u003Cp>Your firm was not able to demonstrate systems that would enable Safe Chain to comply with a number of verification requirements required by the DSCSA. For example, your document, “Standard Operating Procedure for Suspect &amp; Illegitimate Product” (Suspect &amp; Illegitimate Product SOP) (re-issue date 3\u002F15\u002F21) lacked sufficient detail or instruction to enable Safe Chain to adequately:\u003C\u002Fp>\n\n\u003Cp>o Identify suspect product,\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003Cbr>\no Conduct an investigation (including validating any applicable transaction history and transaction information) to determine whether a suspect product is an illegitimate product in coordination with trading partners,\u003Cbr>\no Handle an illegitimate product notification,\u003Cbr>\no Handle a request for verification of a suspect product from FDA,\u003Cbr>\no Make notifications of cleared product, and\u003Cbr>\no Maintain adequate records relating to the investigation of suspect product or the disposition of illegitimate product.\u003C\u002Fp>\n\n\u003Cp>Your firm’s failure to establish and implement systems to enable your compliance with these DSCSA requirements may have resulted in suspect product entering the supply chain rather than the product being quarantined as required by section 582(c)(4)(A)(i)(I) of the FD&amp;C Act. For example, an email from February 6, 2021 from the California Board of Pharmacy to Safe Chain, explains that Safe Chain distributed Gentek lot CCXKVA (discussed in more detail in section 2 below) to White Cross Pharmacy and that this lot lacked the required&nbsp;\u003Cstrong>(b)(4)\u003C\u002Fstrong> and the original induction seal had been removed and replaced with a non-genuine seal.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> A physical examination of the product may have prevented the lot from being distributed.\u003C\u002Fp>\n\n\u003Cp>Your firm’s Suspect &amp; Illegitimate Product SOP also contained information inconsistent with the DSCSA. Specifically, the SOP stated that if “SCS [Safe Chain Solutions] receives confirmation the product is illegitimate or potentially fraudulent an FDA form 3911 will be filed. Disposition of the product will depend on guidance received from the FDA.” As written, this SOP indicated that the firm is expecting guidance from FDA upon submission of a 3911, and disposition of the product depends on such guidance. However, disposition of illegitimate product is your responsibility and is not dependent on FDA’s response to a FDA Form 3911. (FD&amp;C Act section 582(c)(4)(B)).\u003C\u002Fp>\n\n\u003Cp>In addition, your document “Standard Operating Procedures for Vendor and Transaction History Authentication” (re-issue date 4\u002F1\u002F21) contained information inconsistent with the DSCSA. The document indicated that in case of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>,” your firm should contact the Maryland Board of Pharmacy and the FDA within 3 days. However, the DSCSA requires a trading partner that determines a product in its possession or control is an illegitimate product to notify the FDA within 24 hours of making such a determination. (FD&amp;C Act section 582(c)(4)(B)(ii)). (FDA understands “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\n\n\u003Cp>Your lack of sufficient written procedures, or other systems related to compliance with the verification requirements of the DSCSA, rendered your firm unable to demonstrate compliance with the verification requirements of the section 582(c)(4) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>2. Your firm conducted transactions with trading partners that were not authorized (FD&amp;C Act Section 582(c)(3)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The DSCSA requires that trading partners of wholesale distributors meet the applicable requirements for being \u003Cem>authorized\u003C\u002Fem> trading partners. (FD&amp;C Act Section 582(c)(3)). To be authorized, a wholesale drug distributor must have a valid license under State law or section 583 of the FD&amp;C Act, in accordance with section 582(a)(6) of the FD&amp;C Act, and comply with the licensure reporting requirements in section 503(e) of the FD&amp;C Act. (FD&amp;C Act Section 581(2)(B)). Under section 503(e)(2)(A) of the FD&amp;C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\u003C\u002Fp>\n\n\u003Cp>Your firm has a written procedure to verify a trading partner’s status, “Standard Operating Procedures for Trading Partner Validation” (re-issue date of 3\u002F15\u002F21) (Trading Partner Validation SOP). This procedure recognizes that \u003Cstrong>(b)(4)\u003C\u002Fstrong> as defined by the DSCSA. Your Trading Partner Validation SOP even goes so far as to provide the link to FDA’s publicly accessible database of WDDs and 3PLs that have reported their state licensure status to FDA: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fwdd3plreporting\u002Findex.cfm. Your firm, however, did not adhere to this SOP and failed to verify that all of your trading partners reported licensure information to FDA.\u003C\u002Fp>\n\n\u003Cp>Between July, 2020 and March, 2021, your firm purchased drug products from wholesale drug distributors that were not authorized trading partners according to sections 581(2) and 503(e) of the FD&amp;C Act. For example, your firm purchased prescription drug products from wholesale distributors Gentek and Boulevard 9229 LLC. However, FDA has no record of Gentek or Boulevard 9229 LLC ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&amp;C Act. In addition, Boulevard 9229 LLC provided your firm with a fraudulent license. Therefore, Boulevard 9229 LLC not only failed to report to FDA, but it was also never appropriately licensed as required by section 503(e)(1)(A) and 582(a)(6) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>The importance of the requirement that trading partners of wholesale distributors be authorized is highlighted by the fact that, on multiple occasions, your firm was notified that it had received prescription drug products containing different medication than was purported to be present based on the product labeling, making those products suspect product and unfit for distribution. For example, on multiple occasions your firm was notified by trading partners that patients reported receiving bottles of a product labeled as Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) that in fact contained different tablets instead of the Biktarvy tablets.\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Your firm purchased Biktarvy (lot CCXKVA) from Gentek on July 28, 2020. Subsequently, on July 29, 2020, your firm sold bottles from this lot to pharmacy trading partner White Cross. On November 23, 2020, Gilead Sciences, Inc., the manufacturer of Biktarvy, notified your firm that a bottle from lot CCXKVA that was dispensed by White Cross to a patient contained different tablets instead of Biktarvy tablets.\u003C\u002Fli>\n\t\u003Cli>On September 30, 2020, your firm purchased Biktarvy from Gentek (lot CDFYCA) and subsequently sold it to Medicine Shoppe Pharmacy #1802. On October 14, 2020, your firm was notified through an email from World Wide Pharma Sales that a patient returned a bottle of Biktarvy (lot CDFYCA) to the pharmacy because it contained a different medication than was purported to be present based on the product labeling. Furthermore, in another email from World Wide Pharma Sales, from November 24, 2020, you were notified of yet another patient complaint concerning lot CDFYCA. A second patient had retuned a bottle of Biktarvy (lot CDFYCA) to the same pharmacy because it also contained a different medication than was purported to be present based on the product labeling.\u003C\u002Fli>\n\t\u003Cli>On January 7, 2021, your firm purchased Biktarvy from Gentek for a third time (lot CCZCFA), having already been informed that two prior lots purchased from this firm contained bottles of a medication that was different than what was purported to be present based on the product labeling. Safe Chain subsequently sold the product to Medicine Shoppe Pharmacy #1802. Safe Chain discovered that the drug product purchased in this third lot also contained multiple tablets of a different product than should have been present based on the product’s label. A letter from Safe Chain to Gilead indicates that your firm knew of the issue with this third lot by February 12, 2021.\u003C\u002Fli>\n\t\u003Cli>On March 1, 2021, your firm purchased Biktarvy (lot CDSFFA) from Boulevard 9229 LLC. In a letter to your customer, dated March 27, 2021, Safe Chain reported a quality complaint regarding this product. The drug product purchased contained multiple tablets of a different product than should have been present based on the product’s label.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>These instances are especially concerning from a public health perspective given that Biktarvy is indicated to treat a serious health condition, HIV-1 infection, and the recommended dosage for adult and pediatric patients is one pill daily. As explained in the Patient Counseling Information section of the Prescribing Information for Biktarvy, “it is important to take BIKTARVY on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance.” Patients who receive the wrong drug product from the pharmacy may not be able to take the prescribed dose in a timely manner which can cause serious adverse health consequences. In addition, FDA-approved Biktarvy bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious and even life-threatening adverse effects. The boxed warning addresses risks including post treatment acute exacerbation of Hepatitis B.\u003C\u002Fp>\n\n\u003Cp>Your firm continued to purchase product from the same unauthorized trading partners, which resulted in acquiring more suspect product from those entities after they had previously sold you suspect product. This is extremely concerning from a public health perspective given the serious health condition Biktarvy is indicated for. In FDA’s 2016 final guidance \u003Cem>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification\u003C\u002Fem>, FDA warns trading partners that purchasing from a source that a trading partner knows or has reason to believe has engaged in questionable business practices could significantly increase the chance of suspect product entering the pharmaceutical distribution supply chain.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>3. Your firm failed to maintain records of suspect product investigations (FD&amp;C Act Section 582(c)(4)(A)(iii)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>The DSCSA requires that wholesale distributors maintain records of investigations of suspect product for not less than 6 years. (FD&amp;C Act section 582(c)(4)(A)(iii)). Your firm was both unable to provide any written documentation of what products were held in or released from quarantine, and unable to provide records explaining how suspect product was quarantined. In addition, while you were able to produce some correspondence pertaining to the various lots of suspect product, you were unable to provide records about when and how investigations took place to determine whether suspect product was illegitimate.\u003C\u002Fp>\n\n\u003Cp>For example, in a letter from Safe Chain’s outside counsel to Gilead, dated February 12, 2021, you indicate that you would quarantine Biktarvy lot CCZCFA when it was returned to you by the dispenser. The letter explains that Safe Chain notified your immediate trading partner, but does not clarify whether you were referring to a dispenser trading partner or your supplier, Gentek. Your letter also explains that Gentek advised you to destroy the product. However, you were not able to produce records demonstrating that you quarantined the product, any notice you shared about the suspect product with Gentek or other immediate trading partners, or records of the disposition of the product.\u003C\u002Fp>\n\n\u003Cp>Also, your firm could not produce adequate records pertaining to three other suspect product investigations for which Safe Chain made notifications of illegitimate product to the FDA using Form FDA 3911. These Form FDA 3911s were submitted on March 25, 2021 (lots CCXKVA and CDFYCA), March 27, 2021 (lot CDSFFA), and April 7, 2021. (Lot CCZCFA was included on the March 25, 2021 Form FDA 3911 as well.) While these FDA Form 3911s provide some insight into actions Safe Chain claims to have taken, you were not able to provide documentation supporting these actions. As a result, FDA is unable to determine if, or at what point, the drugs referred to in the FDA Form 3911s were appropriately quarantined, as required by section 582(c)(4)(A)(i)(I) of the FD&amp;C Act, and whether investigations were conducted in coordination with trading partners, as required by section 582(c)(4)(A)(i)(II) of the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>4. Your firm failed to respond to a notification of illegitimate product (FD&amp;C Act Section 582(c)(4)(B)(iii)).\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Upon receiving a notification of illegitimate product, a wholesale distributor must identify all illegitimate product subject to such notification in its possession or control, including any product that is subsequently received. (FD&amp;C Act section 582(c)(4)(B)(iii)). You are also required to quarantine such product within your possession or control from product intended for distribution (FD&amp;C Act sections 582(c)(4)(A)(i)(I) and 582(c)(4)(B)(i)(I)) and investigate the product as suspect product (FD&amp;C Act sections 582(c)(4)(A)(i)(II) and 582(c)(4)(B)(iii)). You were not able to provide evidence that you appropriately responded to notifications of illegitimate product.\u003C\u002Fp>\n\n\u003Cp>For example, you emailed Gilead regarding Biktarvy Lot CDGXKA in October 2020. You were informed in an email response from Gilead to Safe Chain dated October 9, 2020, that the transaction history in your records was inconstant with Gilead’s records and that Gilead considers the product to be illegitimate product. You were not able to provide any further information about Lot CDGXKA and whether your firm investigated or quarantined the product.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Your Response to the FDA Form 483\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has reviewed your June 1, 2022 response to our Form FDA 483 in detail and your response is inadequate for the following reasons:\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>FDA understands that your firm hired a third-party consulting firm after FDA’s inspection to assist in reviewing and enhancing all the company’s SOPs. However, your firm’s new SOP, “Handling and Reporting Suspect and\u002For Illegitimate Products” (effective 5\u002F5\u002F22) contains information not consistent with the DSCSA. For example, the SOP indicates that immediate trading partners be notified \u003Cstrong>(b)(4)\u003C\u002Fstrong> after Safe Chain makes a determination that product in its possession or control is illegitimate product. FDA reiterates that the DSCSA requires immediate trading partners to be notified within 24 hours of an illegitimate product determination. (FD&amp;C Act section 582(c)(4)(B)(ii)). FDA notes that the revised SOP you provided, “Vendor and Transaction History Authentication” (effective 5\u002F9\u002F15) is updated with the correct time-frame. However, the inconsistency between the two SOPs creates the potential for significant confusion and untimely notification.\u003C\u002Fli>\n\t\u003Cli>In your response you state that you have: “…NEVER knowingly purchased illegitimate products from any of our Vendors…” (emphasis in original). You explain that you continued to purchase products from Gentek, and did not cease sales of the product, even after becoming aware of issues with product received from the firm because the products were part of an ongoing investigation and you believed the issue was at the retailer\u002Fpharmacy level.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>Your response is inadequate because you failed to provide any documentation demonstrating the rationale for your belief that the issue was at the retailer\u002Fpharmacy level. If your firm had conducted the required investigations, which would have included your firm’s knowledge of reported issues with the drug, you may have recognized the inherent risk of these Gentek products to the supply chain. Furthermore, your response appears to acknowledge that your efforts to look into the problematic product was limited to Safe Chain and Safe Chain’s attorneys. If this is the case, this is inadequate because the DSCSA requires that investigations of suspect product take place in coordination with trading partners. (FD&amp;C Act section 582(c)(4)(A)(i)(II)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>DSCSA Resources\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As explained above, your firm has failed to comply with a number of DSCSA provisions. Please see the FDA guidance documents listed below for additional information about the DSCSA requirements noted above:\u003Csup>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>\u003C\u002Fp>\n\n\u003Cul>\n\t\u003Cli>Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload\u003C\u002Fli>\n\t\u003Cli>Definitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\u003C\u002Fli>\n\t\u003Cli>Verification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Draft Guidance for Industry, March 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\u003C\u002Fli>\n\t\u003Cli>Identifying Trading Partners Under the Drug Supply Chain Security Act, Draft Guidance for Industry, July 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F159621\u002Fdownload.\u003C\u002Fli>\n\u003C\u002Ful>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Safe Chain’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Safe Chain because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\u003C\u002Fp>\n\n\u003Cp>Correct any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice, including seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\u003C\u002Fp>\n\n\u003Cp>Please send your electronic reply to ORAPHARM1_Responses@FDA.HHS.GOV and “cc” Compliance Officer, Emmanuel Ramos (Emmanuel.Ramos@fda.hhs.gov). Your written notification should refer to the Warning Letter #636044 and include FEI number 3009729473.\u003C\u002Fp>\n\n\u003Cp>If you have questions regarding the contents of this letter, please contact Emmanuel Ramos, Compliance Officer, via email at Emmanuel.Ramos@fda.hhs.gov or by telephone at 240-507-7119.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Lisa Harlan\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Pharmaceutical Quality Operations, Division I\u003Cbr>\nU.S. Food &amp; Drug Administration\u003C\u002Fp>\n\n\u003Cp>_______________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> “Suspect product” and “illegitimate product” are defined in sections 581(21) and (8) of the FD&amp;C Act, respectively.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> Trading partners should be mindful of product that is missing required information or security features, as that may indicate the product should be considered suspect. See FDA’s 2016 final \u003Cem>guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>3\u003C\u002Fstrong>\u003C\u002Fem> Draft guidances, when finalized, will represent the agency's current thinking on the topic.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nMr. Charles D. Boyd\n\nRecipient Title\n\nFounder and Chief Executive Officer\n\nSafe Chain Solutions, LLC\n\n822 Chesapeake Drive\n\nCambridge, MD 21613-9408\n\nUnited States\n\nIssuing Office:\n\nDivision of Pharmaceutical Quality Operations I\n\nUnited States\n\nWarning Letter #636044\n\nJune 08, 2023\n\nDear Mr. Boyd:\n\nThe U.S. Food and Drug Administration (FDA) inspected your wholesale drug distribution facility, Safe Chain Solutions, LLC (Safe Chain), FEI 3009729473, at 822 Chesapeake Drive, Cambridge, Maryland from April 11 to May 11, 2022.\n\nThe Drug Supply Chain Security Act (DSCSA) (Title II of Public Law 113-54), enacted by Congress on November 27, 2013, added Section 582 to the Federal Food, Drug, and Cosmetic Act (FD&C Act). Section 582 of the FD&C Act (21 U.S.C. 360eee-1) states the requirements that certain entities in the pharmaceutical distribution supply chain (including wholesale drug distributors) must follow related to product tracing, verification, and authorized trading partners. This warning letter summarizes significant violations of the requirements found in section 582(c) of the FD&C Act. These requirements are intended to help preserve the security of the supply chain for certain prescription drug products, thereby protecting patients from exposure to drugs that may be counterfeit, stolen, contaminated, or otherwise harmful.\n\nFDA issued a Form FDA 483 to Safe Chain at its Cambridge, MD headquarters on May 10, 2022. FDA reviewed your firm’s response, dated June 1, 2022.\n\nFDA has observed that Safe Chain did not have adequate verification systems in place in violation of section 582(c)(4)(A) & (B) of the FD&C Act. FDA observed that Safe Chain failed to maintain records regarding suspect product investigations in violation of section 582(c)(4)(A)(iii) of the FD&C Act, and failed to respond to a notification of illegitimate product in violation of section 582(c)(4)(B)(iii) of the FD&C Act. In addition, Safe Chain engaged in transactions with unauthorized trading partners in violation of section 582(c)(3) of the FD&C Act. Failure to comply with any of the requirements under section 582 of the FD&C Act is a prohibited act under section 301(t) of the FD&C Act (21 U.S.C. 331(t)).\n\nDSCSA Violations\n\nDuring FDA’s inspection, our investigators observed that your firm failed to comply with various requirements of the DSCSA. Specific violations include, but may not be limited to, the following:\n\n1. Your firm failed to have systems in place to enable compliance with the verification requirements of the DSCSA (FD&C Act Section 582(c)(4)(A) & (B)).\n\nUnder section 582(c)(4)(A) & (B) of the FD&C Act, wholesale drug distributors must have systems in place to enable the wholesale distributor to comply with the verification requirements of the DSCSA.\n\nYour firm was not able to demonstrate systems that would enable Safe Chain to comply with a number of verification requirements required by the DSCSA. For example, your document, “Standard Operating Procedure for Suspect & Illegitimate Product” (Suspect & Illegitimate Product SOP) (re-issue date 3\u002F15\u002F21) lacked sufficient detail or instruction to enable Safe Chain to adequately:\n\no Identify suspect product,1\n\no Conduct an investigation (including validating any applicable transaction history and transaction information) to determine whether a suspect product is an illegitimate product in coordination with trading partners,\n\no Handle an illegitimate product notification,\n\no Handle a request for verification of a suspect product from FDA,\n\no Make notifications of cleared product, and\n\no Maintain adequate records relating to the investigation of suspect product or the disposition of illegitimate product.\n\nYour firm’s failure to establish and implement systems to enable your compliance with these DSCSA requirements may have resulted in suspect product entering the supply chain rather than the product being quarantined as required by section 582(c)(4)(A)(i)(I) of the FD&C Act. For example, an email from February 6, 2021 from the California Board of Pharmacy to Safe Chain, explains that Safe Chain distributed Gentek lot CCXKVA (discussed in more detail in section 2 below) to White Cross Pharmacy and that this lot lacked the required (b)(4) and the original induction seal had been removed and replaced with a non-genuine seal.2 A physical examination of the product may have prevented the lot from being distributed.\n\nYour firm’s Suspect & Illegitimate Product SOP also contained information inconsistent with the DSCSA. Specifically, the SOP stated that if “SCS [Safe Chain Solutions] receives confirmation the product is illegitimate or potentially fraudulent an FDA form 3911 will be filed. Disposition of the product will depend on guidance received from the FDA.” As written, this SOP indicated that the firm is expecting guidance from FDA upon submission of a 3911, and disposition of the product depends on such guidance. However, disposition of illegitimate product is your responsibility and is not dependent on FDA’s response to a FDA Form 3911. (FD&C Act section 582(c)(4)(B)).\n\nIn addition, your document “Standard Operating Procedures for Vendor and Transaction History Authentication” (re-issue date 4\u002F1\u002F21) contained information inconsistent with the DSCSA. The document indicated that in case of “(b)(4),” your firm should contact the Maryland Board of Pharmacy and the FDA within 3 days. However, the DSCSA requires a trading partner that determines a product in its possession or control is an illegitimate product to notify the FDA within 24 hours of making such a determination. (FD&C Act section 582(c)(4)(B)(ii)). (FDA understands “(b)(4).\n\nYour lack of sufficient written procedures, or other systems related to compliance with the verification requirements of the DSCSA, rendered your firm unable to demonstrate compliance with the verification requirements of the section 582(c)(4) of the FD&C Act.\n\n2. Your firm conducted transactions with trading partners that were not authorized (FD&C Act Section 582(c)(3)).\n\nThe DSCSA requires that trading partners of wholesale distributors meet the applicable requirements for being authorized trading partners. (FD&C Act Section 582(c)(3)). To be authorized, a wholesale drug distributor must have a valid license under State law or section 583 of the FD&C Act, in accordance with section 582(a)(6) of the FD&C Act, and comply with the licensure reporting requirements in section 503(e) of the FD&C Act. (FD&C Act Section 581(2)(B)). Under section 503(e)(2)(A) of the FD&C Act, wholesale distributors must report to FDA, on an annual basis, “each State by which the person is licensed and the appropriate identification number of each such license; the name, address, and contact information of each facility at which, and all trade names under which, the person conducts business;” and “any significant disciplinary actions.”\n\nYour firm has a written procedure to verify a trading partner’s status, “Standard Operating Procedures for Trading Partner Validation” (re-issue date of 3\u002F15\u002F21) (Trading Partner Validation SOP). This procedure recognizes that (b)(4) as defined by the DSCSA. Your Trading Partner Validation SOP even goes so far as to provide the link to FDA’s publicly accessible database of WDDs and 3PLs that have reported their state licensure status to FDA: https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fwdd3plreporting\u002Findex.cfm. Your firm, however, did not adhere to this SOP and failed to verify that all of your trading partners reported licensure information to FDA.\n\nBetween July, 2020 and March, 2021, your firm purchased drug products from wholesale drug distributors that were not authorized trading partners according to sections 581(2) and 503(e) of the FD&C Act. For example, your firm purchased prescription drug products from wholesale distributors Gentek and Boulevard 9229 LLC. However, FDA has no record of Gentek or Boulevard 9229 LLC ever submitting the required annual reports to FDA regarding state licensure as required by section 503(e) of the FD&C Act. In addition, Boulevard 9229 LLC provided your firm with a fraudulent license. Therefore, Boulevard 9229 LLC not only failed to report to FDA, but it was also never appropriately licensed as required by section 503(e)(1)(A) and 582(a)(6) of the FD&C Act.\n\nThe importance of the requirement that trading partners of wholesale distributors be authorized is highlighted by the fact that, on multiple occasions, your firm was notified that it had received prescription drug products containing different medication than was purported to be present based on the product labeling, making those products suspect product and unfit for distribution. For example, on multiple occasions your firm was notified by trading partners that patients reported receiving bottles of a product labeled as Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) that in fact contained different tablets instead of the Biktarvy tablets.\n\nYour firm purchased Biktarvy (lot CCXKVA) from Gentek on July 28, 2020. Subsequently, on July 29, 2020, your firm sold bottles from this lot to pharmacy trading partner White Cross. On November 23, 2020, Gilead Sciences, Inc., the manufacturer of Biktarvy, notified your firm that a bottle from lot CCXKVA that was dispensed by White Cross to a patient contained different tablets instead of Biktarvy tablets.\n\nOn September 30, 2020, your firm purchased Biktarvy from Gentek (lot CDFYCA) and subsequently sold it to Medicine Shoppe Pharmacy #1802. On October 14, 2020, your firm was notified through an email from World Wide Pharma Sales that a patient returned a bottle of Biktarvy (lot CDFYCA) to the pharmacy because it contained a different medication than was purported to be present based on the product labeling. Furthermore, in another email from World Wide Pharma Sales, from November 24, 2020, you were notified of yet another patient complaint concerning lot CDFYCA. A second patient had retuned a bottle of Biktarvy (lot CDFYCA) to the same pharmacy because it also contained a different medication than was purported to be present based on the product labeling.\n\nOn January 7, 2021, your firm purchased Biktarvy from Gentek for a third time (lot CCZCFA), having already been informed that two prior lots purchased from this firm contained bottles of a medication that was different than what was purported to be present based on the product labeling. Safe Chain subsequently sold the product to Medicine Shoppe Pharmacy #1802. Safe Chain discovered that the drug product purchased in this third lot also contained multiple tablets of a different product than should have been present based on the product’s label. A letter from Safe Chain to Gilead indicates that your firm knew of the issue with this third lot by February 12, 2021.\n\nOn March 1, 2021, your firm purchased Biktarvy (lot CDSFFA) from Boulevard 9229 LLC. In a letter to your customer, dated March 27, 2021, Safe Chain reported a quality complaint regarding this product. The drug product purchased contained multiple tablets of a different product than should have been present based on the product’s label.\n\nThese instances are especially concerning from a public health perspective given that Biktarvy is indicated to treat a serious health condition, HIV-1 infection, and the recommended dosage for adult and pediatric patients is one pill daily. As explained in the Patient Counseling Information section of the Prescribing Information for Biktarvy, “it is important to take BIKTARVY on a regular dosing schedule with or without food and to avoid missing doses as it can result in development of resistance.” Patients who receive the wrong drug product from the pharmacy may not be able to take the prescribed dose in a timely manner which can cause serious adverse health consequences. In addition, FDA-approved Biktarvy bears a boxed warning, commonly referred to as a “black box warning,” which is the strongest warning FDA requires, indicating that the drug carries a significant risk of serious and even life-threatening adverse effects. The boxed warning addresses risks including post treatment acute exacerbation of Hepatitis B.\n\nYour firm continued to purchase product from the same unauthorized trading partners, which resulted in acquiring more suspect product from those entities after they had previously sold you suspect product. This is extremely concerning from a public health perspective given the serious health condition Biktarvy is indicated for. In FDA’s 2016 final guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, FDA warns trading partners that purchasing from a source that a trading partner knows or has reason to believe has engaged in questionable business practices could significantly increase the chance of suspect product entering the pharmaceutical distribution supply chain.\n\n3. Your firm failed to maintain records of suspect product investigations (FD&C Act Section 582(c)(4)(A)(iii)).\n\nThe DSCSA requires that wholesale distributors maintain records of investigations of suspect product for not less than 6 years. (FD&C Act section 582(c)(4)(A)(iii)). Your firm was both unable to provide any written documentation of what products were held in or released from quarantine, and unable to provide records explaining how suspect product was quarantined. In addition, while you were able to produce some correspondence pertaining to the various lots of suspect product, you were unable to provide records about when and how investigations took place to determine whether suspect product was illegitimate.\n\nFor example, in a letter from Safe Chain’s outside counsel to Gilead, dated February 12, 2021, you indicate that you would quarantine Biktarvy lot CCZCFA when it was returned to you by the dispenser. The letter explains that Safe Chain notified your immediate trading partner, but does not clarify whether you were referring to a dispenser trading partner or your supplier, Gentek. Your letter also explains that Gentek advised you to destroy the product. However, you were not able to produce records demonstrating that you quarantined the product, any notice you shared about the suspect product with Gentek or other immediate trading partners, or records of the disposition of the product.\n\nAlso, your firm could not produce adequate records pertaining to three other suspect product investigations for which Safe Chain made notifications of illegitimate product to the FDA using Form FDA 3911. These Form FDA 3911s were submitted on March 25, 2021 (lots CCXKVA and CDFYCA), March 27, 2021 (lot CDSFFA), and April 7, 2021. (Lot CCZCFA was included on the March 25, 2021 Form FDA 3911 as well.) While these FDA Form 3911s provide some insight into actions Safe Chain claims to have taken, you were not able to provide documentation supporting these actions. As a result, FDA is unable to determine if, or at what point, the drugs referred to in the FDA Form 3911s were appropriately quarantined, as required by section 582(c)(4)(A)(i)(I) of the FD&C Act, and whether investigations were conducted in coordination with trading partners, as required by section 582(c)(4)(A)(i)(II) of the FD&C Act.\n\n4. Your firm failed to respond to a notification of illegitimate product (FD&C Act Section 582(c)(4)(B)(iii)).\n\nUpon receiving a notification of illegitimate product, a wholesale distributor must identify all illegitimate product subject to such notification in its possession or control, including any product that is subsequently received. (FD&C Act section 582(c)(4)(B)(iii)). You are also required to quarantine such product within your possession or control from product intended for distribution (FD&C Act sections 582(c)(4)(A)(i)(I) and 582(c)(4)(B)(i)(I)) and investigate the product as suspect product (FD&C Act sections 582(c)(4)(A)(i)(II) and 582(c)(4)(B)(iii)). You were not able to provide evidence that you appropriately responded to notifications of illegitimate product.\n\nFor example, you emailed Gilead regarding Biktarvy Lot CDGXKA in October 2020. You were informed in an email response from Gilead to Safe Chain dated October 9, 2020, that the transaction history in your records was inconstant with Gilead’s records and that Gilead considers the product to be illegitimate product. You were not able to provide any further information about Lot CDGXKA and whether your firm investigated or quarantined the product.\n\nYour Response to the FDA Form 483\n\nFDA has reviewed your June 1, 2022 response to our Form FDA 483 in detail and your response is inadequate for the following reasons:\n\nFDA understands that your firm hired a third-party consulting firm after FDA’s inspection to assist in reviewing and enhancing all the company’s SOPs. However, your firm’s new SOP, “Handling and Reporting Suspect and\u002For Illegitimate Products” (effective 5\u002F5\u002F22) contains information not consistent with the DSCSA. For example, the SOP indicates that immediate trading partners be notified (b)(4) after Safe Chain makes a determination that product in its possession or control is illegitimate product. FDA reiterates that the DSCSA requires immediate trading partners to be notified within 24 hours of an illegitimate product determination. (FD&C Act section 582(c)(4)(B)(ii)). FDA notes that the revised SOP you provided, “Vendor and Transaction History Authentication” (effective 5\u002F9\u002F15) is updated with the correct time-frame. However, the inconsistency between the two SOPs creates the potential for significant confusion and untimely notification.\n\nIn your response you state that you have: “…NEVER knowingly purchased illegitimate products from any of our Vendors…” (emphasis in original). You explain that you continued to purchase products from Gentek, and did not cease sales of the product, even after becoming aware of issues with product received from the firm because the products were part of an ongoing investigation and you believed the issue was at the retailer\u002Fpharmacy level.\n\nYour response is inadequate because you failed to provide any documentation demonstrating the rationale for your belief that the issue was at the retailer\u002Fpharmacy level. If your firm had conducted the required investigations, which would have included your firm’s knowledge of reported issues with the drug, you may have recognized the inherent risk of these Gentek products to the supply chain. Furthermore, your response appears to acknowledge that your efforts to look into the problematic product was limited to Safe Chain and Safe Chain’s attorneys. If this is the case, this is inadequate because the DSCSA requires that investigations of suspect product take place in coordination with trading partners. (FD&C Act section 582(c)(4)(A)(i)(II)).\n\nDSCSA Resources\n\nAs explained above, your firm has failed to comply with a number of DSCSA provisions. Please see the FDA guidance documents listed below for additional information about the DSCSA requirements noted above:3\n\nDrug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification, Final Guidance, June 2021, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F88790\u002Fdownload\n\nDefinitions of Suspect Product and Illegitimate Product for Verification Obligations Under the Drug Supply Chain Security Act, Final Guidance for Industry, March 2023, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F111468\u002Fdownload.\n\nVerification Systems Under the Drug Supply Chain Security Act for Certain Prescription Drugs, Draft Guidance for Industry, March 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F117950\u002Fdownload.\n\nIdentifying Trading Partners Under the Drug Supply Chain Security Act, Draft Guidance for Industry, July 2022, https:\u002F\u002Fwww.fda.gov\u002Fmedia\u002F159621\u002Fdownload.\n\nConclusion\n\nSafe Chain’s response to FDA Form 483 does not indicate that sufficient remediation efforts have been taken. FDA is sending this compliance letter to Safe Chain because of the inherent risk to the supply chain when firms do not comply with the provisions of the DSCSA.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of violations that exist at your facility. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations.\n\nCorrect any violations promptly. Failure to promptly and adequately address these violations may result in regulatory or legal action without further notice, including seizure and injunction.\n\nThis letter notifies you of our findings and provides you an opportunity to address the above deficiencies. After you receive this letter, respond to this office in writing within 15 working days. Specify what you have done to address any violations and to prevent their recurrence. In response to this letter, you may provide additional information for our consideration as we continue to assess your activities and practices. If you cannot complete corrective actions within 15 working days, state your reasons for delay and your schedule for completion.\n\nPlease send your electronic reply to ORAPHARM1_Responses@FDA.HHS.GOV and “cc” Compliance Officer, Emmanuel Ramos (Emmanuel.Ramos@fda.hhs.gov). Your written notification should refer to the Warning Letter #636044 and include FEI number 3009729473.\n\nIf you have questions regarding the contents of this letter, please contact Emmanuel Ramos, Compliance Officer, via email at Emmanuel.Ramos@fda.hhs.gov or by telephone at 240-507-7119.\n\nSincerely,\n\n\u002FS\u002F\n\nLisa Harlan\n\nProgram Division Director\n\nOffice of Pharmaceutical Quality Operations, Division I\n\nU.S. Food & Drug Administration\n\n_______________________\n\n1 “Suspect product” and “illegitimate product” are defined in sections 581(21) and (8) of the FD&C Act, respectively.\n\n2 Trading partners should be mindful of product that is missing required information or security features, as that may indicate the product should be considered suspect. See FDA’s 2016 final guidance Drug Supply Chain Security Act Implementation: Identification of Suspect Product and Notification.\n\n3 Draft guidances, when finalized, will represent the agency's current thinking on the topic.","Safe Chain Solutions, LLC","safe-chain-solutions-llc-636044-06082023","2026-08-18T06:42:29.145918+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fsafe-chain-solutions-llc-636044-06082023","2026-10-26T08:09:52.58375+00:00","Closed Out","2023-06-27","636044","2025-03-17","Mr. Charles D. Boyd","2026-08-20T01:00:46.064+00:00","Via Email","2023-06-08",{"id":118,"raw":119,"subject":123,"body_html":124,"body_text":125,"firm_name":126,"letter_id":127,"created_at":18,"fei_number":19,"letter_url":128,"updated_at":129,"action_type":22,"case_status":23,"posted_date":130,"marcs_cms_no":131,"product_type":26,"closeout_date":19,"issuing_office":75,"recipient_name":132,"body_fetched_at":133,"delivery_method":115,"recipient_title":19,"reference_number":19,"action_taken_date":134,"medical_device_id":19,"response_letter_date":19},1338,[120,121,122,75,123,13,13,13],"\u003Ctime datetime=\"2024-07-30T13:20:00Z\">07\u002F30\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-07-25T04:00:00Z\">07\u002F25\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024\">Skin Beauty Solutions\u003C\u002Fa>","Finished Pharmaceuticals\u002FUnapproved New Drugs","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Email\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Cassandra Pryor\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Skin Beauty Solutions\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>P.O. Box 25527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Saint Paul\u003C\u002Fspan>, \u003Cspan>MN\u003C\u002Fspan> \u003Cspan>55125-0527\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:info@skinbeautysolutions.com\"> info@skinbeautysolutions.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Drug Evaluation and Research (CDER)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>July 25, 2024\u003C\u002Fp>\n\n\u003Cp>RE: 683006\u003C\u002Fp>\n\n\u003Cp>Dear Cassandra Pryor:\u003C\u002Fp>\n\n\u003Cp>This letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup>, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act), 21 U.S.C. 355(a) and 331(d).\u003C\u002Fp>\n\n\u003Cp>The Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Unapproved New Drugs\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Based on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&amp;C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\u003C\u002Fp>\n\n\u003Cp>Examples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\u003C\u002Fp>\n\n\u003Cp>\u003Cu>LACTIC Acid Skin Chemical Peel 90%\u003C\u002Fu>\u003Cbr>\n• “lactic acid skin peel 90%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells”\u003C\u002Fp>\n\n\u003Cp>• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>GLYCOLIC ACID Skin Cosmetic Grade Peel 70%\u003C\u002Fu>\u003Cbr>\n• “glycolic acid skin peel 70%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nPrevents Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>Combination Peel GLYCOLIC 35% LACTIC 45%\u003C\u002Fu>\u003Cbr>\n• “combination peel\u003Cbr>\nGlycolic Acid 35%\u003Cbr>\nLactic Acid 45%\u003Cbr>\nClears Acne &amp; Scars\u003Cbr>\nRemoves Dead Skin Cells\u003Cbr>\nSmoothes [sic] Fine lines &amp; Wrinkles”\u003C\u002Fp>\n\n\u003Cp>\u003Cu>SALICYLIC ACID Skin Chemical Peel 30%\u003C\u002Fu>\u003Cbr>\n• “salicylic acid skin peel 30%\u003Cbr>\nRemoves Blackheads\u003Cbr>\nClears Acne &amp; Scars”\u003C\u002Fp>\n\n\u003Cp>• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\u003C\u002Fp>\n\n\u003Cp>Your chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&amp;C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&amp;C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&amp;C Act, 21 U.S.C. 331(d) and 355(a).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nTina Smith, M.S.\u003Cbr>\nCaptain, U.S. Public Health Service\u003Cbr>\nDirector\u003Cbr>\nOffice of Unapproved Drugs and Labeling Compliance\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Drug Evaluation and Research\u003Cbr>\nFood and Drug Administration\u003C\u002Fp>\n\n\u003Cp>___________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Email\n\nProduct:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nCassandra Pryor\n\nRecipient Title\n\nManager\n\nSkin Beauty Solutions\n\nP.O. Box 25527\n\nSaint Paul, MN 55125-0527\n\nUnited States\n\ninfo@skinbeautysolutions.com\n\nIssuing Office:\n\nCenter for Drug Evaluation and Research (CDER)\n\nUnited States\n\nWARNING LETTER\n\nJuly 25, 2024\n\nRE: 683006\n\nDear Cassandra Pryor:\n\nThis letter is to advise you that the United States Food and Drug Administration (FDA) reviewed your website, at the internet address https:\u002F\u002Fwww.skinbeautysolutions.com\u002F in April 2024 and has observed that your website offers numerous chemical peel drug products; including, multiple strengths of lactic acid, glycolic acid, combination glycolic and lactic acid, and salicylic acid products1, including “LACTIC Acid Skin Chemical Peel 90%,” “GLYCOLIC ACID Skin Cosmetic Grade Peel 70%,” “Combination Peel GLYCOLIC 35% LACTIC 45%,” and “SALICYLIC ACID Skin Chemical Peel 30%” (hereinafter referred to as your “chemical peels”) for sale in the United States. As described below, your chemical peels are unapproved new drugs introduced or delivered for introduction into interstate commerce in violation of sections 505(a) and 301(d) of the Federal Food, Drug, and Cosmetic Act (FD&C Act), 21 U.S.C. 355(a) and 331(d).\n\nThe Agency is concerned about potent chemical peel products that are available to be purchased and used by consumers. Such products pose a public health risk because they can cause skin injuries such as burns on the area of application, wounds, pain, swelling, and scarring. FDA has received adverse event reports of injuries involving use of such products, some of which required emergency room care, specialty care from a dermatologist, and\u002For surgical intervention.\n\nUnapproved New Drugs\n\nBased on a review of your website, your firm’s chemical peels are drugs under section 201(g)(1) of the FD&C Act, 21 U.S.C. 321(g)(1), because they are intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease and\u002For intended to affect the structure or any function of the body.\n\nExamples of claims observed on your website https:\u002F\u002Fwww.skinbeautysolutions.com\u002F that establish the intended use of these products as drugs include, but may not be limited to, the following:\n\nLACTIC Acid Skin Chemical Peel 90%\n\n• “lactic acid skin peel 90%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells”\n\n• “Chemical peels work by loosening and gently sloughing off the damaged, unattractive skin cells. . .. Lactic Peels can also work on the deeper layers of skin to accelerate the skin’s natural production of collagen and elastin.”\n\nGLYCOLIC ACID Skin Cosmetic Grade Peel 70%\n\n• “glycolic acid skin peel 70%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nPrevents Fine lines & Wrinkles”\n\nCombination Peel GLYCOLIC 35% LACTIC 45%\n\n• “combination peel\n\nGlycolic Acid 35%\n\nLactic Acid 45%\n\nClears Acne & Scars\n\nRemoves Dead Skin Cells\n\nSmoothes [sic] Fine lines & Wrinkles”\n\nSALICYLIC ACID Skin Chemical Peel 30%\n\n• “salicylic acid skin peel 30%\n\nRemoves Blackheads\n\nClears Acne & Scars”\n\n• “SALICYLIC ACID SKIN CHEMICAL PEEL W\u002F BETA HYDROXY (BHA) BY SKIN BEAUTY SOLUTIONS – IDEAL FOR ACNE, BLACKHEADS, DERMATITIS, WHITEHEADS, CLOGGED PORES.”\n\nYour chemical peels are not generally recognized as safe and effective for the above referenced uses and, therefore, are “new drugs” under section 201(p) of the FD&C Act, 21 U.S.C. 321(p). Subject to certain exceptions not applicable here, new drugs may not be legally introduced or delivered for introduction into interstate commerce without an approved application from FDA in effect, as described in sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a). No FDA-approved applications pursuant to section 505 of the FD&C Act, 21 U.S.C. 355, are in effect for these products. Accordingly, the introduction or delivery for introduction into interstate commerce of these products violates sections 301(d) and 505(a) of the FD&C Act, 21 U.S.C. 331(d) and 355(a).\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction. Please notify FDA in writing, within fifteen working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to U.S. Food and Drug Administration, CDER\u002FOC\u002FOffice of Unapproved Drugs and Labeling Compliance by email to FDAAdvisory@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nTina Smith, M.S.\n\nCaptain, U.S. Public Health Service\n\nDirector\n\nOffice of Unapproved Drugs and Labeling Compliance\n\nOffice of Compliance\n\nCenter for Drug Evaluation and Research\n\nFood and Drug Administration\n\n___________________\n\n1 We have observed that your website offers Lactic Acid skin peel 35%, 50%, 70%, 90% strengths, Glycolic Acid skin peel buffered and unbuffered 35%, 50%, 70% strengths, combination Glycolic Acid 35% and Lactic Acid 45% strength, and Salicylic Acid skin chemical peels 10%, 20%, and 30% strengths.","Skin Beauty Solutions","skin-beauty-solutions-683006-07252024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fskin-beauty-solutions-683006-07252024","2026-10-26T08:09:58.469498+00:00","2024-07-30","683006","Cassandra Pryor","2026-08-19T23:55:45.859+00:00","2024-07-25",6,{"510k":137,"classification":138,"enforcement":139,"event":140,"event_backfill":141,"pma":142,"warning_letter":143},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-18T04:00:44.748+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]